National Essential Medicines List of Afghanistan

2014
Preface

With thanks to God for enabling us, we present this revision of the national essential medicines list (EML) and the licensed medicines list (LML) of Afghanistan. These documents are critical to the delivery of quality health services across the country. The policy of the Ministry of Public Health (MoPH) of the Islamic Republic of Afghanistan includes ensuring that the population of Afghanistan has access to safe, effective, and affordable medicines to treat its primary health problems. The EML includes the medicines needed for adequately addressing the priority health problems defined in the MoPH’s health strategy. The LML includes the medicines listed in the EML and additional medicines for conditions not included as priorities in the present strategy and medicines used in private sector.

The MoPH developed and published the national EML of Afghanistan for the first time in 1995; the last revision and publication occurred in 2007. The EML and LML should be regularly revised in response to the rapid expansion of basic health services in Afghanistan since 2003, the changing of internationally and nationally recommended treatment protocols for some diseases, the presence of new and emergent diseases, and the withdrawal of medicines for which safer alternatives have become available from treatment guidelines.

To revise the EML and LML, the MoPH authorized the National Medicine Selection Committee (NMSC) to develop a detailed procedure for inclusion or exclusion of medicines from the 2007 lists. The database for tracking updates and edits was also revised, and some new necessary information was added. These procedures will facilitate the mechanism of including new medicines in the EML or LML using logical and comprehensive methods. This procedure conforms to a specific format, guaranteeing the inclusion of new medicines in a scientific and transparent way.

I would like to express my appreciation to the members of the NMSC who oversaw and managed the complicated process of updating the lists. The MoPH is also grateful to the many Afghan and international organizations and individuals who provided assistance and support in the process. We are especially grateful for the sustained technical and financial assistance of the US Agency for International Development (USAID), through the Strengthening Pharmaceutical Systems (SPS) project in Afghanistan, and to the World Health Organization (WHO) Eastern Mediterranean Regional Office, which facilitated the successful revision, publication, and distribution of the updated EML and LML of Afghanistan.

The MoPH warmly recommends that its partners in the public health sector who contribute to the implementation of the basic package of health services (BPHS) and the essential package of hospital services (EPHS) use the EML as the official reference. Likewise, the MoPH warmly recommends that its partners in the private sector who are involved in the production, importation, or distribution of medicines use the LML as an official reference. The use of these two lists will benefit all those working with pharmaceuticals in Afghanistan and will improve their collaboration with the MoPH as it strives to provide quality health services to the people of Afghanistan.

Dr. Suraya Daili
Minister of Public Health Kabul, Afghanistan, July 2014
<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>List of Contributors and Collaborators</td>
<td>4</td>
</tr>
<tr>
<td>Abbreviations and Acronyms</td>
<td>6</td>
</tr>
<tr>
<td>Introduction</td>
<td>7</td>
</tr>
<tr>
<td>Short History</td>
<td>7</td>
</tr>
<tr>
<td>Objectives of the Update</td>
<td>7</td>
</tr>
<tr>
<td>Transparent Review Process of EML</td>
<td>8</td>
</tr>
<tr>
<td>Classifications of Medicines</td>
<td>9</td>
</tr>
<tr>
<td>Procedures for the Inclusion of New Products</td>
<td>9</td>
</tr>
<tr>
<td>Computerization</td>
<td>10</td>
</tr>
<tr>
<td>Medicine Listings in the EML</td>
<td>10</td>
</tr>
<tr>
<td>Detailed Instructions for Use of the EML</td>
<td>10</td>
</tr>
<tr>
<td>Where to Obtain Copies and Updates of the EML</td>
<td>12</td>
</tr>
<tr>
<td>Essential Medicines List</td>
<td>13</td>
</tr>
<tr>
<td>Anatomical Therapeutic Chemical Classification</td>
<td>13</td>
</tr>
<tr>
<td>Essential Medicines List Alphabetical Index</td>
<td>42</td>
</tr>
<tr>
<td>Special Programs List</td>
<td>52</td>
</tr>
<tr>
<td>National Family Planning Program List</td>
<td>52</td>
</tr>
<tr>
<td>National Postpartum Hemorrhage Program List</td>
<td>52</td>
</tr>
<tr>
<td>National HIV/AIDS Program List and National Drug Demand Reduction List</td>
<td>52</td>
</tr>
<tr>
<td>HIV/AIDS Medicines</td>
<td>52</td>
</tr>
<tr>
<td>National Drug Demand Reduction Medicines</td>
<td>53</td>
</tr>
<tr>
<td>National Malaria and Leishmania Control Program List</td>
<td>53</td>
</tr>
<tr>
<td>National Tuberculosis Program List</td>
<td>54</td>
</tr>
<tr>
<td>National Leprosy Program List</td>
<td>54</td>
</tr>
<tr>
<td>National EPI Program List</td>
<td>55</td>
</tr>
<tr>
<td>Reference Table for Vitamin and Mineral Supplements</td>
<td>55</td>
</tr>
<tr>
<td>General</td>
<td>58</td>
</tr>
<tr>
<td>Types of Applications</td>
<td>58</td>
</tr>
<tr>
<td>Submittal and Screening Process</td>
<td>59</td>
</tr>
<tr>
<td>Detailed Description of the Application Form</td>
<td>60</td>
</tr>
<tr>
<td>Notes on the Application Process</td>
<td>65</td>
</tr>
<tr>
<td>References</td>
<td>68</td>
</tr>
</tbody>
</table>
List of Contributors and Collaborators

The following individuals and organizations contributed to different stages in the revision of the National EML and LML.

National Medicine Selection Committee members

- **Working group members**
  Pharmacist Abdul Hafiz Quraishi, General Director, the General Directorate of Pharmaceutical Affairs (GDPA)
  Pharmacist Abdul Khalil Khazlad, Director of Avicenna Pharmaceutical Institute (API)
  Pharmacist Mohammad Zafar Omari, Chief of Party, SPS
  Dr. M. Rafi Rahmani, MD, Professor in the Pharmacology Department, Kabul Medical University, Head of the Committee
  Pharmacist Haji M. Naimi, Professor and Lecturer, Faculty of Pharmacy, Kabul University
  Dr. Abdul Samad Omar, MD, Professor in Surgery, Dean of Medical Faculty, Kabul Medical University
  Dr. M. Amin Asghari, MD, Clinical Professor and Head of the Internal Medicine Ward, Wazir Akbar Khan Hospital (WAKH)
  Dr. M. Fayaz Safi, MD, Associate Professor, Afghanistan Physicians Association
  Pharmacist Nematullah Nawrozian, Head of Medicine Information Center, API
  Pharmacist Mohammad Asif Yari, Technical Advisor, SPS
  Dr. Ahmad Eklil Hayat, Grant and Contract Management Unit (GCMU)
  Dr. Safiullah Nadeeb, MD, National Professional Officer WHO
  Pharmacist Mohammad Dawood Mahsoomi, Lecturer, Ghazanfar Institute of Health Science
  Pharmacist Abdul Zahir Siddiqui, Pharmaceutical Services and Field Coordination Program Manager, SPS
  Pharmacist Fahima Habibi, Medicine Resource General Manager, API
  Pharmacist Mohammad Nazir Haidarzad, GDPA Coordinator
  Pharmacist Shekeba Yusoufzai, Essential Medicine Manager, API
  Pharmacist Marzia Abdullah, Medicine Calcification Manager, API
  Pharmacist Mohammad Naser Isalm, National Formulary Manager, API
  Pharmacist Shakilla Amarkhil, Afghanistan Nationwide Pharmacy Association
  Dr. Paul Ickx, Senior Principal Technical Advisor, SPS

- **Technical Subcommittee members**
  Pharmacist Aeysha Noorzai, Ministry of Higher Education
  Dr. Sultan Mohammad Naji, Head, Chest Surgery Department, Ibn Sina Hospital
  Drs. Palwasha Alizai, gynecology and obstetrics specialist
  Dr. Shreen Alam, trainer, specialist in burn care
  Dr. Mohammad Aref Ibrahim, ear, nose and throat specialist
  Dr. Monir Ahmad Yosoufi, Assistant Chief, Anesthesia Department, Rabia Balkhi Hospital
  Dr. Jawed Shohab, trainer, specialist in hematology
  Drs. Anisa Hezat, specialist in stomatology
  Dr. Abdul Ghafoor Hatef, orthopedic specialist
  Dr. Abdul Khalid Amini, SPS
  Dr. Yama Noorzad, orthopedic specialist
  Pharmacist Said Mohammad Sajjadi, API
  Dr. Mohammad Haroon Rasuli,
  Dr. Nabil Pakteen, trainer, specialist in cardiac and respiratory diseases
  Dr. Ahmad Walid YosoufZai, trainer, specialist in hematology
Dr. Abdul Moqadas Frozan, specialist in skin disease  
Pharmacist Mohammad Nabi Akhtari, API  
Dr. Sakhi Ahmad Amiri, specialist in infectious diseases  
Dr. Emal Aziz Jabarkhil, specialist in mental and neurological disorders  
Dr. Sayed Najibullah Jawed, specialist in mental disorders  
Pharmacist Abdullah Jawad, API  
Drs. Roqia Naser, MoPH  
Dr. Abdul Wali, Ibni Sina Hospital  
Dr. Motwali Younousi, MoPH  
Professor Mohammad Hassan Frostan, Faculty of Pharmacy  
Dr. Rasheda Formoly, MoPH  
Dr. Hamida Hamid, National Malaria and Leishmania Control Program  
Dr. Mohammad Yonous Bargami, National HIV/AIDS Program  
Dr. Khaled Raheen, National Program of TB Control  
Dr. Sher Zaman, National Program of TB Control  
Dr. Ahamad Wali Amini, MoPH Nutrition Department  
Pharmacist Emal Safi, Sardar Mohd Dawood Hospital  
Pharmacist Faizullah Lutfi, API  
Dr. Bashir Ahmad Sarwari, Mental Health Department MoPH  
Dr. Sher Ahmad Rahmanzai, Afghanistan Nation Medicines Services Organization  
Professor Shafiq Mashal, Faculty of Pharmacy, Kabul University  
Dr. Hafizullah Mahmudi, SPS  
Dr. Ahamad Shah Pardis, WHO  
Dr. Mohammad Seddiq Faizi, MoPH  

**Contributing MoPH departments and partner institutions**  
- Health Management Information System Department, MoPH  
- HIV/AIDS and Drug Demand Reduction Department, MoPH  
- Mental Health Department, MoPH  
- Family Planning Department, MoPH  
- Nutrition Department, MoPH  
- Reproductive Health Department, MoPH  
- Integrated Management of Childhood Illness (IMCI) Department, MoPH  
- Malaria and Leishmania Control Program, MoPH  
- GCMU, MoPH  
- Policy and Planning Department, MoPH  
- National Tuberculosis Institute, MoPH  
- World Health Organization, Eastern Mediterranean Regional Office  
- Strengthening Pharmaceutical Systems Project funded by USAID
### Abbreviations and Acronyms

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADHA</td>
<td>attention deficit hyperactivity disorder</td>
</tr>
<tr>
<td>API</td>
<td>Avicenna Pharmaceutical Institute</td>
</tr>
<tr>
<td>ATC</td>
<td>Anatomical Therapeutic Chemical</td>
</tr>
<tr>
<td>BCC</td>
<td>bacillus Calmette-Guérin (TB vaccine)</td>
</tr>
<tr>
<td>BHC</td>
<td>basic health center</td>
</tr>
<tr>
<td>BPHS</td>
<td>basic package of health services</td>
</tr>
<tr>
<td>CHC</td>
<td>comprehensive health center</td>
</tr>
<tr>
<td>DH</td>
<td>district hospital</td>
</tr>
<tr>
<td>EML</td>
<td>essential medicines list</td>
</tr>
<tr>
<td>EPHS</td>
<td>essential package of hospital services</td>
</tr>
<tr>
<td>EPI</td>
<td>Expanded Programme on Immunization [WHO]</td>
</tr>
<tr>
<td>g</td>
<td>gram</td>
</tr>
<tr>
<td>GCMU</td>
<td>Grant and Contract Management Unit</td>
</tr>
<tr>
<td>GDPA</td>
<td>General Directorate of Pharmaceutical Affairs</td>
</tr>
<tr>
<td>HIV/AIDS</td>
<td>human immunodeficiency virus/acquired immunodeficiency syndrome</td>
</tr>
<tr>
<td>HP</td>
<td>health post</td>
</tr>
<tr>
<td>HSC</td>
<td>health subcenter</td>
</tr>
<tr>
<td>IMCI</td>
<td>Integrated Management of Childhood Illness [WHO]</td>
</tr>
<tr>
<td>Inj</td>
<td>Injection</td>
</tr>
<tr>
<td>INN</td>
<td>international nonproprietary name</td>
</tr>
<tr>
<td>IU</td>
<td>international units</td>
</tr>
<tr>
<td>L</td>
<td>liter</td>
</tr>
<tr>
<td>LML</td>
<td>licensed medicines list</td>
</tr>
<tr>
<td>mcg</td>
<td>microgram</td>
</tr>
<tr>
<td>mEq</td>
<td>milliequivalent</td>
</tr>
<tr>
<td>mg</td>
<td>milligram</td>
</tr>
<tr>
<td>MLEM</td>
<td>Model List of Essential Medicines [WHO]</td>
</tr>
<tr>
<td>MHT</td>
<td>mobile health team</td>
</tr>
<tr>
<td>mmol</td>
<td>millimole</td>
</tr>
<tr>
<td>MoPH</td>
<td>Ministry of Public Health</td>
</tr>
<tr>
<td>mOsm</td>
<td>milliosmole</td>
</tr>
<tr>
<td>MSH</td>
<td>Management Sciences for Health</td>
</tr>
<tr>
<td>NDDR</td>
<td>National Drug Demand Reduction</td>
</tr>
<tr>
<td>NGO</td>
<td>nongovernmental organization</td>
</tr>
<tr>
<td>NLP</td>
<td>National Leprosy Program</td>
</tr>
<tr>
<td>NMLP</td>
<td>National Malaria and Leishmania Control Program</td>
</tr>
<tr>
<td>NMSC</td>
<td>National Medicine Selection Committee</td>
</tr>
<tr>
<td>NTP</td>
<td>National Tuberculosis Program</td>
</tr>
<tr>
<td>Or</td>
<td>Oral</td>
</tr>
<tr>
<td>ORS</td>
<td>oral rehydration salts</td>
</tr>
<tr>
<td>Osm</td>
<td>osmole</td>
</tr>
<tr>
<td>pce</td>
<td>Piece</td>
</tr>
<tr>
<td>PH</td>
<td>provincial hospital</td>
</tr>
<tr>
<td>PPH</td>
<td>postpartum hemorrhage</td>
</tr>
<tr>
<td>REACH</td>
<td>Rural Expansion of Afghanistan’s Community-Based Health Care</td>
</tr>
<tr>
<td>RH</td>
<td>regional hospital</td>
</tr>
<tr>
<td>SPS</td>
<td>Strengthening Pharmaceutical Systems</td>
</tr>
<tr>
<td>STG</td>
<td>standard treatment guideline</td>
</tr>
<tr>
<td>TB</td>
<td>tuberculosis</td>
</tr>
<tr>
<td>TFU</td>
<td>therapeutic feeding unit</td>
</tr>
<tr>
<td>TSC</td>
<td>technical selection committee</td>
</tr>
<tr>
<td>USAID</td>
<td>United States Agency for International Development</td>
</tr>
<tr>
<td>USAN</td>
<td>United States Adopted Name</td>
</tr>
<tr>
<td>vit</td>
<td>vitamin</td>
</tr>
<tr>
<td>WG</td>
<td>working group</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
</tbody>
</table>
Introduction

Short History

In 1995 the Ministry of Public Health (MoPH) first published a national essential drugs list (now called the Essential Medicines List [EML]) with the collaboration of the World Health Organization (WHO). In 2003 the EML, which contained 255 items, was republished in collaboration with the USAID-funded Rural Expansion of Afghanistan’s Community-Based Health Care (REACH) project and WHO. In 2005, an Licensed Medicine List (LML) for Afghanistan, was published with the financial and technical aid of REACH and WHO. Both lists were revised in 2007 in collaboration with the USAID-funded Tech-Serve Project and WHO. The EML contains all the medicines recommended for use in the Basic Package of Health Services (BPHS), Essential Package of Hospital Services (EPHS), and the MoPH’s national programs.

Given the quick development and expansion of the health service delivery system in Afghanistan since 2003, including the development of new treatment protocols and updated WHO recommendations for several diseases as well as withdrawal of some medicines from treatment protocols due to severe adverse drug reactions or the emergence of safer substitutes, the need for updating the EML became urgent. The MoPH constituted a National Medicine Selection Committee (NMSC) in 2012, with a core working group consisting of clinical and pharmaceutical experts from the MoPH, major hospitals, teaching institutes, international agencies, nongovernmental organizations (NGOs), and the private sector. The working group met regularly, delegating the in-depth revision of certain parts of the EML and LML to different subcommittees, drawing in the contribution of a still larger group of experts from the different MoPH task forces, training institutes, NGOs, and international organizations. On October 29, 2013, a draft was presented at a one-day workshop, attended by 112 participants including the Deputy Minister of MoPH, provincial health directorates, pharmacy and medical specialists, provincial pharmacy officers, and representatives of NGOs and private sectors working in health sector. The draft was scrutinized and finalized through intensive group work.

Objectives of the Update

The main objectives of the review process were to—

- Ensure consistency between the BPHS, EPHS, EML, and LML documents based on a rational selection of essential medicines
- Elaborate clear terms of reference for the NMSC, not only for this exercise, but also for revisions in the future
- Adapt the EML to the medicines recommended in the national standard treatment guideline (STG) for the primary level at BPHS level
- Define a detailed and transparent review process that can be used for future revisions
- Define detailed and transparent procedures to control possible exceptions to the EML with administrative and budgetary methods. Similar procedures should apply to requests for deletion of a product that is on the EML or addition of a new entry
**Transparent Review Process of EML**

Under the guidance and supervision of the General Directorate of Pharmaceutical Affairs (GDPA), the NMSC adhered to the following transparent review process in all stages of the revision to allow future reference to the decisions made.

- Both a clear definition of what documents need to be produced (the EML and LML) and clear procedures for inclusion of new medicines in the lists were provided.

- Working principles were agreed upon, including the management of the review task force and the inclusive consultation of interested parties and stakeholders, without creating a slow and cumbersome process. Realistic deadlines for different stages in the review process were set.

- A list of the reference works that should guide the review process was compiled and included the following:
  - The existing EML
  - The WHO Model List of Essential Medicines (MLEM)—used as the primary guide on efficacy, safety, and quality
  - The Afghan BPHS and EPHS documents
  - Recently updated treatment recommendations from MoPH departments and programs
  - Product lists of recognized international suppliers—a good guide to evaluate availability and cost
  - The *British National Formulary, PubMed* and *Martindale*—when other references failed to provide enough information

- Specific selection criteria for inclusion in the EML were defined, including the following:
  - Medicines listed on the WHO MLEM may be included to ensure efficacy, safety, and quality.
  - Medicines listed in the BPHS and EPHS should be included.
  - Medicines recommended in the STG should be included.
  - Included medicines should be available in Afghanistan to ensure access.
  - Included medicines should be available from recognized international suppliers to ensure access and affordable cost.
  - Medicines already donated by international donors should be included to ensure access and affordable cost for certain essential medicines.
Classifications of Medicines

The medicines in the EML are grouped according to the Anatomical Therapeutic Chemical (ATC) classification, promoted by the WHO Collaborating Centre for Drug Statistics Methodology. The medicines are sorted into 14 main groups (first level), with one pharmacological or therapeutic subgroup (second level). The third and fourth levels are the chemical, pharmacological, and therapeutic subgroups, and the fifth level is the chemical substance. The second, third, and fourth levels are often used to identify pharmacological subgroups when that is considered more appropriate than therapeutic or chemical subgroups. For example, ampicillin is classified as follows:

<table>
<thead>
<tr>
<th>ATC Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J</td>
<td>Anti-infective for systemic use (main group)</td>
</tr>
<tr>
<td>J01</td>
<td>Antibacterial for systemic use (therapeutical subgroup)</td>
</tr>
<tr>
<td>J01C</td>
<td>Beta-lactam antibacterial, penicillins (chemical subgroup)</td>
</tr>
<tr>
<td>J01CA</td>
<td>Penicillins with extended spectrum (chemical subgroup)</td>
</tr>
<tr>
<td>J01CA01</td>
<td>Ampicillin (chemical substance)</td>
</tr>
</tbody>
</table>

Thus each chemical substance in the EML has its seven-digit ATC code. A chemical substance can have more than one ATC code, if it is used for different therapeutic purposes. The same substance listed under different administration forms or presentations will have the same ATC code, if the different forms are used for the same therapeutic purpose. The ATC code is not a unique identifier for each individual medicine included in the EML.

If it exists, the international nonproprietary name (INN) is used for the chemical substance. If the INN is not available, either the United States Adopted Name (USAN) or the British Approved Name or other standard name is chosen.

The ATC classification was chosen for the following reasons:

- It contains defined daily doses for many of the products listed.
- It will facilitate studies on consumption of medicines in Afghanistan.
- It will allow a comparison of studies of Afghanistan’s pharmaceutical system with studies from other countries.
- It has an equivalent classification system for herbal medicines and veterinary products.
- It is flexible enough to allow temporary classification of a group of products until a specific code is found.

The ATC classification is updated regularly by WHO. The MoPH decided to use the January 2012 version and has adapted the system for use in Afghanistan. The adapted ATC is available from the MoPH on request. The MoPH will not update the ATC classification used in Afghanistan annually, but rather it will most likely do an update every five years.

Procedures for the Inclusion of New Products

The committee drafted detailed instructions for updating and including new products in the EML. The request form and detailed user guides are included in annex A.
Computerization

The GDPA will track future updates and changes in the EML using a database. Presently the database contains all the generic names of the medicines contained in the EML and LML, including recent deletions. For each medicine, the following information is tracked:

- Classification code based on the WHO ATC classification (January 2012 version)
- INN, strength, and presentation—matching, to the extent possible, the name used in the WHO ATC classification
- Alternate generic name under which the medicine is known in Afghanistan
- Median international indicator price and local price, if available
- Whether the medicine is—
  - Included in the EML or LML of Afghanistan
  - Used in the BPHS, the EPHS, or both at this presentation and strength
  - On the controlled substances list of Afghanistan
  - Available without prescription
  - Included in a special program of the MoPH (which may entail restrictions on importation and use)
  - Included in the WHO MLEM (2013 version)

Tracking the medicines using a database allows for the easy production of customized listings for different purposes and also for the storing of historical data on products that are no longer used. This database module has become the core of a more extended database used by the MoPH to track all registered medicines in Afghanistan.

Medicine Listings in the EML

The EML contains an ATC listing of medicines recommended for use in the public sector. Chemical substances are listed under their INN and preparation details, indicating whether and at what level they are recommended for use in the BPHS, the EPHS, or both. If a substance is used for different therapeutic purposes, that substance will be listed under each corresponding group, with a different ATC code. Items are listed in sections up to the third level only. More detailed classification was deemed needlessly cumbersome.

The EML also lists the items included in special lists separately, for use by specific programs of the MoPH. These items are part of the EML, but some are restricted for use by the specific programs of the MoPH as indicated in the special programs lists.

Detailed Instructions for Use of the EML

- The EML contains all items allowable for use in the public sector. The MoPH recommends limiting medicine donations to items and strengths listed in the EML.
contains all medicines recommended for use in the BPHS and EPHS.

- Several medicines are listed for use only in special programs (e.g., opium tincture for the substance abuse program, antiretroviral medicines for the HIV program, misoprostol for the postpartum hemorrhage program). Please refer to the instructions for appropriate use under each program.

- The following presentation forms are interchangeable, meaning that if one is mentioned, the others are allowable as well:
  
  o Tablets and capsules for oral administration are interchangeable, but sustained-release tablets or capsules are not interchangeable with normal tablets or capsules.
  
  o Creams, ointments, and gels for topical administration are interchangeable.
  
  o Solutions, syrups, suspensions, and powder for oral administration are interchangeable, but these forms are not interchangeable with oral tablets or capsules.
  
  o Solutions and powders for injectable solution are interchangeable, but aqueous and oily solutions are not interchangeable. Normal injections and retard, sustained-release, or long-acting injections are not interchangeable.

  **Example:** Amoxicillin 250 mg capsule is listed; amoxicillin 250 mg tablet is accepted as well. Bacitracin ointment is listed; bacitracin cream is accepted as well.

  **Note:** If an oral form is listed, this inclusion does not mean that a topical or injectable form is accepted.

- If the volume of a bottle or the weight of a container or tube is mentioned, they will often correspond to a full treatment of the most common patient population using that medicine. The explicitly mentioned volume and weight are minimum limits (i.e., smaller containers will not be accepted, but larger containers are acceptable).

  **Example:** Co-trimoxazole oral ingestion suspension 50 ml is listed; co-trimoxazole 40 ml is not acceptable; co-trimoxazole 60 ml or 100 ml are acceptable.

- Vitamins and minerals are included in a two different sections:
  
  o Individual vitamins and minerals are listed in the main list, with exact specifications. Most often these preparations are used for therapeutic purposes.
  
  o Multivitamins with or without minerals are allowable, as long as the concentration of each active substance per unit dose (e.g., tablet, ml, 5 ml) falls within the limits for supplement daily intake listed in the “Reference Table for Vitamins and Minerals Supplements” section (table 3). Everything on this table is not necessarily included in the present version of EML or LML. Most often these preparations are used as dietary supplements.

- Oral rehydration salts (ORS) are listed in two forms: 20.5 g/L and 27.9 g/L. The 20.5 g/L solution is recommended by WHO and likewise by the MoPH. All BPHS and EPHS implementers should use the solution given in table 1.
Table 1. Composition of ORS 20.5 g/L

<table>
<thead>
<tr>
<th>Powder for Dilution in 1 L</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucose</td>
<td>75 mEq</td>
</tr>
<tr>
<td>Sodium</td>
<td>75 mEq or mmol/L</td>
</tr>
<tr>
<td>Chloride</td>
<td>65 mEq or mmol/L</td>
</tr>
<tr>
<td>Potassium</td>
<td>20 mEq or mmol/L</td>
</tr>
<tr>
<td>Citrate</td>
<td>10 mmol/L</td>
</tr>
<tr>
<td>Osmolarity</td>
<td>245 mOsm/L</td>
</tr>
<tr>
<td>Glucose</td>
<td>13.5 g/L</td>
</tr>
<tr>
<td>Sodium chloride</td>
<td>2.6 g/L</td>
</tr>
<tr>
<td>Potassium chloride</td>
<td>1.5 g/L</td>
</tr>
<tr>
<td>Trisodium citrate dihydrate a</td>
<td>2.9 g/L</td>
</tr>
</tbody>
</table>

*a Trisodium citrate dihydrate may be replaced by sodium hydrogen carbonate (sodium bicarbonate) 2.5 g/L. Because this latter formulation is quite unstable under tropical conditions, it is recommended only when it is manufactured for immediate use.

ORS ReSoMal® is used only for the management of dehydration in severely malnourished children. Its use is, therefore, dedicated only for therapeutic feeding units (see table 2).

Table 2. Composition of ReSoMal per Liter

| Glucose                   | 125 mmol/L |
| Sodium                   | 45 mmol/L |
| Potassium                | 40 mmol/L |
| Chloride                 | 70 mmol/L |
| Magnesium                | 3 mmol/L |
| Zinc                     | 0.3 mmol/L |
| Copper                   | 0.045 mmol/L |
| Citrate                  | 7 mmol/L |
| Osmolarity               | 300 mmol/L |


Where to Obtain Copies and Updates of the EML

- Printed copies of this version can be obtained from the MoPH, GDPA, API, Essential Medicines Department in Kabul.
- Updated versions will also be available on the websites of the MoPH (www.moph.gov.af) and GDPA (www.gdpa.gov.af).
- For further information please contact at this number: 020-2104659
## Essential Medicines List
### Anatomical Therapeutic Chemical Classification

<table>
<thead>
<tr>
<th>Category and Substance</th>
<th>BPHS</th>
<th>EPHS</th>
<th>Special Program</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>A — ALIMENTARY TRACT AND METABOLISM</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>A02 — MEDICINES FOR ACID-RELATED DISORDERS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>A02A — ANTACIDS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aluminium hydroxide 120 mg + magnesium trisilicate 250 mg per tablet, oral ingestion tablet [A02AD01or]</td>
<td>HP, BHC, CHC, DH</td>
<td></td>
<td>DH, PH, RH</td>
</tr>
<tr>
<td>Aluminium hydroxide 200 mg + magnesium hydroxide 200 mg per tablet, oral chewable tablet [A02AD01or]</td>
<td>HP, HSC, BHC, MHT, CHC, DH</td>
<td></td>
<td>DH, PH, RH</td>
</tr>
<tr>
<td>Aluminium hydroxide 225 mg + magnesium hydroxide 200 mg/5 ml, in 200 ml bottle, oral ingestion suspension [A02AD01or]</td>
<td>HSC, BHC, MHT, CHC, DH</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aluminium hydroxide 500 mg per tablet, oral chewable tablet [A02AB01or]</td>
<td>HSC, BHC, MHT, CHC, DH</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>A02B — MEDICINES FOR PEPTIC ULCER AND GASTROESOPHAGEAL REFLUX DISEASE (GERD)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Omeprazole 20 mg per capsule, oral ingestion capsule [A02BC01or]</td>
<td></td>
<td></td>
<td>PH, RH</td>
</tr>
<tr>
<td>Omeprazole 40 mg per capsule, oral ingestion capsule [A02BC01or]</td>
<td></td>
<td></td>
<td>DH, PH, RH</td>
</tr>
<tr>
<td>Omeprazole 40 mg per vial, injection vial [A02BC01or]</td>
<td></td>
<td></td>
<td>PH, NH</td>
</tr>
<tr>
<td>Ranitidine 150 mg per tablet, oral ingestion tablet [A02BA02or]</td>
<td></td>
<td></td>
<td>DH, PH, RH</td>
</tr>
<tr>
<td>Ranitidine 25 mg/ml, in 2 ml ampoule, injection solution[A02BA02inj]</td>
<td></td>
<td></td>
<td>DH, PH, RH</td>
</tr>
<tr>
<td>Ranitidine 300 mg per tablet, oral ingestion tablet [A02BA02or]</td>
<td></td>
<td></td>
<td>PH, RH</td>
</tr>
<tr>
<td><strong>A03 — MEDICINES FOR FUNCTIONAL GASTROINTESTINAL DISORDERS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>A03B — BELLADONNA AND DERIVATIVES, PLAIN</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atropine sulfate 1 mg/ml, in 1 ml ampoule, injection solution [A03BA01inj]</td>
<td></td>
<td></td>
<td>DH, PH, RH</td>
</tr>
<tr>
<td>Atropine sulfate 1 mg per tablet, oral ingestion tablet [A03BA01or]</td>
<td></td>
<td></td>
<td>PH, RH</td>
</tr>
<tr>
<td>Hyoscine (butylbromide, hydrobromide) 10 mg per tablet, oral ingestion tablet [A03BB01or]</td>
<td></td>
<td></td>
<td>PH, RH</td>
</tr>
<tr>
<td>Hyoscine (butylbromide, hydrobromide) 20 mg/ml, in 1 ml ampoule, injection solution[A03BB01inj]</td>
<td></td>
<td></td>
<td>DH, PH, RH</td>
</tr>
<tr>
<td><strong>A03F — PROPULSIVES</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

EML - Version of July 2014
A06—LAXATIVES

A06A—LAXATIVES

Bisacodyl 5 mg per tablet, oral ingestion tablet [A06AB02or] DH DH, PH, RH
Lactulose 3.33 g/5 ml, in 150 ml bottle, oral ingestion syrup [A06AD11or] CHC, DH DH, PH, RH

A07—ANTIDIARRHEALS, INTESTINAL ANTI-INFLAMMATORY, AND ANTI-INFECTIVE MEDICINES

A07A—INTESTINAL ANTI-INFECTIVES

Nystatin 100,000 IU/ml, in 15 ml, oral topical drop [A07AA02or] HSC, BHC, MHT, CHC, DH DH, PH, RH
Nystatin 100,000 IU per tablet, oral ingestion tablet [A07AA02or] HSC, BHC, MHT, CHC, DH DH, PH, RH
Nystatin 500,000 IU per tablet, oral ingestion tablet [A07AA02or] HSC, BHC, MHT, CHC, DH DH, PH, RH

A07B—INTESTINAL ADSORBENTS

Activated charcoal 1 g per tablet, oral ingestion tablet [A07BA01or] HP, HSC, BHC, MHT, CHC, DH DH, PH, RH
Activated charcoal 500 mg per tablet, oral ingestion tablet [A07BA01or] HP, HSC, BHC, MHT, CHC, DH DH, PH, RH

A07C—ELECTROLYTES WITH CARBOHYDRATES

Oral rehydration salts (ORS), 20.5 g/L, in 1 L sachet, oral ingestion powder [A07CA01or] HP, HSC, BHC, MHT, CHC, DH DH, PH, RH
Oral rehydration salts (ORS), 27.9 g/L, in 1 L sachet, oral ingestion powder [A07CA01or] HP, BHC, CHC, DH DH, PH, RH
Oral rehydration salts (ORS) ReSoMal in 1 L sachet, oral ingestion powder [A07CA01or] PH, RH TFU

A10—MEDICINES USED IN DIABETES

A10A—INSULINS AND ANALOGUES

Insulin isophane (NPH) intermediate 100 IU/ml, in 10 ml vial, injection vial [A10AC03inj] PH, RH
Insulin isophane (NPH) intermediate 40 IU/ml, in 10 ml vial, injection vial [A10AC03inj] RH
Insulin soluble fast 100 IU/ml, in 10 ml vial, injection vial [A10AB01inj] PH, RH
Insulin soluble fast 40 IU/ml, in 10 ml vial, injection vial [A10AB01inj] RH

A10B—BLOOD GLUCOSE LOWERING MEDICINES, EXCLUDING INSULINS
Glibenclamide 5 mg per tablet, oral ingestion tablet [A10BB01or]  
Metformin 500 mg per tablet, oral ingestion tablet [A10BA02or]

**A11—VITAMINS**

**A11A—MULTIVITAMINS, COMBINATIONS**

- Multivitamins and other minerals, including combinations [A11AA03]  
  Multiple micronutrient formulation per sachet (1 g sachet), oral ingestion powder [A11AA02or]  
  \[(iron 10 mg EFF + vit A 400 mcg RE + zinc 4.1 mg Zn G + vit C 30 mg AA + folic acid 90 mcg + vit D3 5.0 mcg + vit E 5.0 mcg TE + vit B1 0.5 mg + vit B2 0.5 mg + vit B6 0.5 mg + vit B12 0.9 mcg + niacin 6.0 mg + copper 0.56 mg CuS + iodine 90 mcg KI + selenium 17 mcg NaS per sachet)\]  
  \[PH, HSC, BHC, MHT, CHC, DH\]  
  \[DH, PH, RH\]

- Multiple micronutrient formulation 500 mg tablet, oral ingestion tablet [A11AA03or]  
  \[(iron 30 mg EFF + vit A 800 mcg RE + zinc 15 mg Zn G + vit C 70 mg AA + folic acid 400 mcg + vit D3 5.0 mcg + vit E 10 mg TE + vit B1 1.4 mg + vit B2 1.4 mg + vit B6 1.9 mg + vit B12 2.6 mcg + niacin 18.0 mg + copper 2.0 mg CuS + iodine 150 mcg KI + selenium 65 mcg NaS per tablet)\]  
  \[PH, HSC, BHC, MHT, CHC, DH\]  
  \[DH, PH, RH\]

**A11C—VITAMINS A AND D, INCLUDING COMBINATIONS OF THE TWO**

- Colecalciferol (vit D3) 600,000 IU/ml, injection ampoule [A11CC05inj]  
  \[CHC, DH\]  
  \[DH, PH, RH\]

- Retinol (oily) (vit A) 100,000 IU/ml, oral solution [A11CA01or]  
  \[PH, BHC, CHC, DH\]  
  \[DH, PH, RH\]

- Retinol (vit A) 100,000 IU per ampoule, injection ampoule [A11CA01inj]  
  \[PH, BHC, CHC, DH\]  
  \[RH\]

- Retinol (vit A) 100,000 IU per tablet, oral ingestion tablet [A11CA01or]  
  \[PH, HSC, BHC, MHT, CHC, DH\]  
  \[DH, PH, RH\]

- Retinol (vit A) 200,000 IU per tablet, oral ingestion tablet [A11CA01or]  
  \[PH, HSC, BHC, MHT, CHC, DH\]  
  \[DH, PH, RH\]

**A11H—OTHER PLAIN VITAMIN PREPARATIONS**

- Folic acid (vit B9) 1 mg per tablet, oral ingestion tablet [A11HA11or]  
  \[PH, BHC, MHT, CHC, DH\]  
  \[DH, PH, RH\]

- Folic acid (vit B9) 5 mg per tablet, oral ingestion tablet [A11HA11or]  
  \[PH, BHC, MHT, CHC, DH\]  
  \[DH, PH, RH\]

- Pyridoxine (vit B6) 25 mg per tablet, oral ingestion tablet [A11HA02or]  
  \[DH\]  
  \[DH, PH, RH\]

- Pyridoxine (vit B6) 40 mg per tablet, oral ingestion tablet [A11HA02or]  
  \[DH\]  
  \[DH, PH, RH\]

**A12—MINERAL SUPPLEMENTS**

**A12A—CALCIUM**

- Calcium gluconate 10% in 10 ml ampoule, injection ampoule [A12AA03inj]  
  \[HSC, BHC, MHT, CHC, DH\]  
  \[PH, RH\]
### A12C—OTHER MINERAL SUPPLEMENTS

<table>
<thead>
<tr>
<th>Supplement Description</th>
<th>Code(s)</th>
<th>Statuses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zinc sulfate 10 mg per tablet, oral ingestion tablet, blister pack of 10</td>
<td>A12CB01or</td>
<td>HP, HSC, BHC, MHT, CHC, DH, PH, RH</td>
</tr>
<tr>
<td>Zinc sulfate 20 mg per tablet, oral ingestion tablet, blister pack of 10</td>
<td>A12CB01or</td>
<td>HP, HSC, BHC, MHT, CHC, DH, PH, RH</td>
</tr>
</tbody>
</table>

### B—BLOOD AND BLOOD-FORMING ORGANS

#### B01—ANTITHROMBOTIC AGENTS

- **B01A—ANTITHROMBOTIC AGENTS**
  - Acetylsalicylic acid (aspirin) 100 mg per tablet, oral ingestion tablet [B01AC06or]
  - Acetylsalicylic acid (aspirin) 325 mg per tablet, oral ingestion tablet [B01AC06or]
  - Enoxaparin 100 mg/ml, in 1 ml ampoule, injection solution [B01AB05inj]
  - Heparin 1,000 IU/ml, in 5 ml ampoule, injection solution [B01AB01inj]
  - Heparin 2,500 IU/ml, in 5 ml ampoule, injection solution [B01AB01inj]
  - Heparin 5,000 IU/ml, in 1 ml ampoule, injection solution [B01AB01inj]

- **B01B—ANTITHROMBOTIC AGENTS**
  - Acetylsalicylic acid (aspirin) 100 mg per tablet, oral ingestion tablet [B01AC06or]
  - Acetylsalicylic acid (aspirin) 325 mg per tablet, oral ingestion tablet [B01AC06or]
  - Enoxaparin 100 mg/ml, in 1 ml ampoule, injection solution [B01AB05inj]
  - Heparin 1,000 IU/ml, in 5 ml ampoule, injection solution [B01AB01inj]
  - Heparin 2,500 IU/ml, in 5 ml ampoule, injection solution [B01AB01inj]
  - Heparin 5,000 IU/ml, in 1 ml ampoule, injection solution [B01AB01inj]

#### B02—ANTIHEMORRHAGICS

- **B02A—ANTIHEMORRHAGICS**
  - Coagulation factor II, VII, IX, X per ampoule, injection solution [B02BD01inj]
  - Heparin 1,000 IU/ml, in 5 ml ampoule, injection solution [B01AB01inj]

- **B02B—ANTIHEMORRHAGICS**
  - Coagulation factor II, VII, IX, X per ampoule, injection solution [B02BD02inj]
  - Heparin 1,000 IU/ml, in 5 ml ampoule, injection solution [B01AB01inj]

#### B03—ANTIANEMIC PREPARATIONS

- **B03A—IRON PREPARATIONS**
  - Ferrous sulfate 125 mg/5 ml, in 120 ml, oral ingestion liquid [B03AA07or]
  - Ferrous sulfate 60 mg per tablet, oral ingestion tablet [B03AA07or]
  - Ferrous sulfate 60 mg + folic acid (vit B9) 0.4 mg per tablet, oral ingestion tablet [B03AD03or]
  - Iron dextran 50 mg/ml, in 2 ml ampoule, injection solution [B03AC06inj]
## B03B—VITAMIN B12 AND FOLIC ACID

<table>
<thead>
<tr>
<th>Description</th>
<th>Strengths</th>
<th>Prescriptions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Folic acid (vit B9) 1 mg per tablet, oral ingestion tablet</td>
<td>HSC, BHC, MHT, CHC, DH</td>
<td>PH, RH</td>
</tr>
<tr>
<td>Folic acid (vit B9) 5 mg per tablet, oral ingestion tablet</td>
<td>HSC, BHC, MHT, CHC, DH</td>
<td>PH, RH</td>
</tr>
<tr>
<td>Hydroxocobalamin (vit B12) 0.5 mg/ml, in 1 ml ampoule, injection solution</td>
<td>HSC, BHC, MHT, CHC, DH</td>
<td>PH, RH</td>
</tr>
<tr>
<td>Hydroxocobalamin (Vit B12) 1 mg/ml, in 1 ml ampoule, injection solution</td>
<td>HSC, BHC, MHT, CHC, DH</td>
<td>PH, RH</td>
</tr>
</tbody>
</table>

## B05—BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS

### B05A—BLOOD AND RELATED PRODUCTS

**Dextran 70 6% injection solution [B05AA05inj]**

### B05B—I.V. SOLUTIONS

**Glucose 4% + sodium chloride 0.18% in 1,000 ml bottle, injection solution [B05BB02inj]**

**Glucose 4% + sodium chloride 0.18% in 500 ml bottle, injection solution [B05BB02inj]**

**Glucose 5% + sodium chloride 0.9% in 1,000 ml bottle, injection solution [B05BB02inj]**

**Glucose 5% + sodium chloride 0.9% in 500 ml bottle, injection solution [B05BB02inj]**

**Glucose 50% injection solution [B05BA03inj]**

**Mannitol 10% in 100 ml bottle, infusion solution [B05BC01inj]**

**Mannitol 20% in 100 ml bottle, infusion solution [B05BC01inj]**

**Ringer’s lactate in 1,000 ml, infusion solution [B05BB02inj]**

**Ringer’s lactate in 500 ml, infusion solution [B05BB02inj]**

**Sodium chloride 0.9% in 1,000 ml bottle, injection solution [B05BB01inj]**

**Sodium chloride 0.9% in 100 ml bottle, injection solution [B05BB01inj]**

**Sodium bicarbonate 1.4% in 20 ml vial, injection vial [B05CB04inj]**

**Sodium bicarbonate 8.4% in 10 ml vial, injection vial [B05CB04inj]**

### B05C—I.RIRRIGATING SOLUTIONS

**Glucose 10% in 1,000 ml bottle, injection solution [B05CX01inj]**

**Glucose 10% in 500 ml bottle, injection solution [B05CX01inj]**

**Glucose 5% in 1,000 ml bottle, injection solution [B05CX01inj]**

**Glucose 5% in 500 ml bottle, injection solution [B05CX01inj]**

**Sodium bicarbonate 1.4% in 20 ml vial, injection vial [B05CB04inj]**

**Sodium bicarbonate 8.4% in 10 ml vial, injection vial [B05CB04inj]**

### B05D—PERITONEAL DIALYTICS

**Peritoneal dialytics, isotonic solutions in 1,000 ml per bag, parenteral solution [B05DA00]**

### B05X—I.V. SOLUTION ADDITIVES

**Potassium chloride 11.2% in 20 ml ampoule, injection solution [B05XA01inj]**

---

EML - Version of July 2014
C—CARDIOVASCULAR SYSTEM

C01—CARDIAC THERAPY

C01A—CARDIAC GLYCOSIDES
Digoxin 0.25 mg/ml, in 2 ml ampoule, injection solution [C01AA05inj] PH, RH
Digoxin 0.25 mg per tablet, oral ingestion tablet [C01AA05or] DH, PH, RH

C01B—ANTIARRHYTHMICS, CLASSES I AND III
Lidocaine 20 mg/ml, in 5 ml ampoule, injection solution [C01BB01inj] RH
Procainamide 100 mg/ml, in 10 ml ampoule, injection solution [C01BA02inj] RH
Procainamide 250 mg per tablet, oral ingestion tablet [C01BA02or] RH

C01C—CARDIAC STIMULANTS EXCLUDING CARDIAC GLYCOSIDES
Dopamine 40 mg/ml, in 5 ml vial, injection solution [C01CA04inj] RH
Epinephrine (adrenaline) 0.1% in 1 ml ampoule, injection solution [C01CA24inj] HSC*, BHC*, MHT*, CHC, DH, PH, RH

C01D—VASODILATORS USED IN CARDIAC DISEASES
Glyceryl trinitrate (nitroglycerine) 0.5 mg per tablet, sublingual-oral tablet [C01DA02or] RH
Isosorbide dinitrate 10 mg per tablet, sublingual-oral tablet [C01DA08or] DH DH, PH, RH
Isosorbide dinitrate 20 mg per tablet, sublingual-oral tablet [C01DA08or] DH DH, PH, RH
Isosorbide dinitrate 5 mg per tablet, sublingual-oral tablet [C01DA08or] DH DH, PH, RH

C02—ANTIHYPERTENSIVES

C02A—ANTIADRENERGIC AGENTS, CENTRALLY ACTING
Methyldopa 250 mg per tablet, oral ingestion tablet [C02AB01or] HSC, BHC, MHT, CHC, DH, PH, RH

C02D—ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON
Hydralazine 20 mg/ml, in 2 ml, injection solution [C02DB01inj] DH DH, PH, RH
Hydralazine 25 mg per tablet, oral ingestion tablet [C02DB02or] RH
Hydralazine 50 mg per tablet, oral ingestion tablet [C02DB02or]  

C03 — DIURETICS

C03A — LOW-CEILING DIURETICS, THIAZIDES
Hydrochlorothiazide 25 mg per tablet, oral ingestion tablet [C03AA03or]  
Hydrochlorothiazide 50 mg per tablet, oral ingestion tablet [C03AA03or]  

C03C — HIGH-CEILING DIURETICS
Furosemide 10 mg/ml, in 2 ml ampoule, injection solution [C03CA01inj]  
Furosemide 20 mg per tablet, oral ingestion tablet [C03CA01or]  
Furosemide 40 mg per tablet, oral ingestion tablet [C03CA01or]  

C03D — POTASSIUM-SPARING AGENTS
Spironolactone 25 mg per tablet, oral ingestion tablet [C03DA01or]  
Spironolactone 50 mg per tablet, oral ingestion tablet [C03DA01or]  

C07 — BETA-BLOCKING AGENTS

C07A — BETA-BLOCKING AGENTS
Atenolol 100 mg per tablet, oral ingestion tablet [C07AB03or]  
Atenolol 25 mg per tablet, oral ingestion tablet [C07AB03or]  
Atenolol 50 mg per tablet, oral ingestion tablet [C07AB03or]  
Metoprolol 1 mg/ml, in 5 ml ampoule, injection solution [C07AB02inj]  
Metoprolol 50 mg per tablet, oral ingestion tablet [C07AB02or]  
Propranolol 10 mg per tablet, oral ingestion tablet [C07AA05or]  
Propranolol 20 mg per tablet, oral ingestion capsule or tablet [C07AA05or]  
Propranolol 40 mg per tablet, oral ingestion tablet [C07AA05or]  

C08 — CALCIUM CHANNEL BLOCKERS

C08C — SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS  
Amlodipine 5 mg per tablet, oral ingestion tablet [C08CA01or]  
Nifedipine slow-release 10 mg per tablet, oral ingestion tablet [C08CA05or]  
Nifedipine slow-release 20 mg per tablet, oral ingestion tablet [C08CA05or]  

EML - Version of July 2014
C08D—SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS

Verapamil 2.5 mg/ml, in 2 ml ampoule, injection solution [C08DA01inj] RH
Verapamil 40 mg per tablet, oral ingestion tablet [C08DA01or] RH
Verapamil 80 mg per tablet, oral ingestion tablet [C08DA01or] RH

C09—AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM

C09A—ACE INHIBITORS, PLAIN
Captorpril 25 mg per tablet, oral ingestion tablet [C09AA01or] RH
Enalapril 10 mg per tablet, oral ingestion tablet [C09AA02or] RH

C10—LIPID-MODIFYING AGENTS

C10A—LIPID-MODIFYING AGENTS, PLAIN
Atorvastatin 20 mg per tablet, oral ingestion tablet [C10AA05or] PH, RH
Cholestyramine (cholestyramine) 4 g per sachet, oral ingestion powder [C10AC01or] PH, RH
Fenofibrate 200 mg per capsule, oral ingestion capsule [C10AB05or] PH, RH

D—DERMATOLOGICALS

D01—ANTIFUNGALS FOR DERMATOLOGICAL USE

D01A—ANTIFUNGALS FOR TOPICAL USE
Ketoconazole 2% in 15 g tube, topical cream [D01AC08] PH, RH
Ketoconazole 2% in 60 ml, topical shampoo [D01AC08] PH, RH
Methylrosaniline (gentian violet) 0.5% in 10 ml bottle, topical solution [D01AE02] HP, HSC, BHC, MHT, CHC, DH DH, PH, RH
Methylrosaniline (gentian violet) 1% in 10 ml bottle, topical solution [D01AE02] HP, HSC, BHC, MHT, CHC, DH DH, PH, RH
Methylrosaniline (gentian violet) 25 g per bottle, topical crystals [D01AE02] HP, BHC, CHC, DH DH, PH, RH
Nystatin 100,000 IU/g, in 25 g tube, topical cream [D01AA01] BHC, CHC, DH PH, RH
Salicylic acid 5%, topical solution [D01AE12] PH, RH
Terbinafine 1% in 30 g tube, topical cream [D01AE15] PH, RH
Tolnaftate 1% topical cream [D01AE18] RH
D01B—ANTIFUNGALS FOR SYSTEMIC USE

Griseofulvin 125 mg per tablet, oral ingestion tablet [D01BA01or] PH, RH
Griseofulvin 250 mg per tablet, oral ingestion tablet [D01BA01or] PH, RH
Griseofulvin 500 mg per tablet, oral ingestion tablet [D01BA01or] PH, RH
Terbinafine 125 mg per tablet, oral ingestion tablet [D01BA02or] PH, RH
Terbinafine 250 mg per tablet, oral ingestion tablet [D01BA02or] PH, RH

D02A—EMOLLIENTS AND PROTECTIVES

D02A—EMOLLIENTS AND PROTECTIVES

Retinol (vit A) 850 IU + colecalfilerol (vit D3) 85 IU/g, in 30 g tube, topical ointment [D02AX00] DH
Zinc oxide 10% in 20 g tube, topical ointment [D02AB01] PH, RH
Zinc oxide 20% in 20 g tube, topical cream [D02AB01] DH, PH, RH

D04A—ANTIPRURITICS, INCLUDING ANTIHISTAMINES, ANESTHETICS, AND OTHERS

D04A—ANTIPRURITICS, INCLUDING ANTIHISTAMINES, ANESTHETICS, AND OTHERS

Calamine (ZnO + Fe2O3) 8% in 30 g tube, topical cream [D04AX01] PH, RH,
Calamine (ZnO + Fe2O3) 8% in 60 ml bottle topical lotion [D04AX01] BHC, CHC, DH
Lidocaine 2% in 15 g tube, topical gel [D04AB04] HSB, BHC, MHT, CHC, DH
Lidocaine 4% topical gel [D04AB04] HSC, BHC, MHT, CHC, DH

D05—ANTIPSORIATICS

D05A—ANTIPSORIATICS FOR TOPICAL USE

Coal tar 5% in 100 g bottle, topical lotion [D05AA01] RH

D06—ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE

D06A—ANTIBIOTICS FOR TOPICAL USE

Bacitracin 500 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51] DH
Mupirocin 2% in 10 g tube, topical cream [D06AX09] DH, PH, RH
D06B—CHEMOTHERAPEUTICS FOR TOPICAL USE
Metronidazole 0.75% in 15 g tube, topical ointment [D06BX01]  
Silver sulfadiazine 1% in 500 g container, topical cream [D06BA01]  
Silver sulfadiazine 1% in 20g tube, topical cream [D06BA01]

D07—CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS

D07A—CORTICOSTEROIDS, PLAIN
Hydrocortisone acetate 1% in 15 g tube, topical cream [D07AA02]

D07C—CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS
Betamethasone 0.1% + neomycin 0.5% in 15 g tube, topical cream [D07CC01]

D08—ANTISEPTICS AND DISINFECTANTS

D08A—ANTISEPTICS AND DISINFECTANTS
Boric acid + glycerin 5% (glycerin boric) in 10 ml, topical solution [D08AD01]  
Cetrimide 15% + chlorhexidine gluconate 1.5% topical solution [D08AC52]  
Chlorhexidine digluconate 7.1% topical solution or gel [D08AC02]  
Chlorhexidine digluconate 5% topical solution [D08AC02]  
Hydrogen peroxide 6% topical solution [D08AX01]  
Potassium permanganate 0.01% topical solution [D08AX06]  
Povidone iodine 10% topical solution [D08AG02]  
Sodium hypochlorite (chlorine) 0.5% topical solution [D08AX07]

D10—ANTI-ACNE PREPARATIONS

D10A—ANTI-ACNE PREPARATIONS FOR TOPICAL USE
Benzoyl peroxide 5% topical cream [D10AE01]  
Benzoyl peroxide 5% topical lotion [D10AE01]  
Sulfur 2% + salicylic acid 1% topical ointment [D10AB02]

G—GENITOURINARY SYSTEM AND SEX HORMONES
### G01 — GYNECOLOGICAL ANTI-INFECTIVES AND ANTISEPTICS

#### G01A — ANTI-INFECTIVES AND ANTISEPTICS, EXCLUDING COMBINATIONS

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Furazolidone 100 mg per tablet, oral ingestion tablet</td>
<td>[G01AX06or]</td>
<td>RH</td>
</tr>
<tr>
<td>Furazolidone 125 mg/5 ml, in 60 ml, oral syrup</td>
<td>[G01AX06or]</td>
<td>RH</td>
</tr>
<tr>
<td>Nystatin 100,000 IU/g, in 15 g tube, vaginal cream</td>
<td>[G01AA01vg]</td>
<td>HSC, BHC, MHT, CHC, DH</td>
</tr>
<tr>
<td>Nystatin 100,000 IU per ovule, vaginal suppository</td>
<td>[G01AA01vg]</td>
<td>BHC, CHC, DH</td>
</tr>
<tr>
<td>Nystatin 100,000 IU per tablet, vaginal tablet</td>
<td>[G01AA01vg]</td>
<td>HSC, BHC, MHT, CHC, DH</td>
</tr>
</tbody>
</table>

### G02 — OTHER GYNECOLOGICALS

#### G02A — OXYTOCICS

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ergometrine maleate 0.2 mg/ml, injection solution</td>
<td>[G02AB03inj]</td>
<td>HSC, BHC, MHT, CHC, DH</td>
</tr>
<tr>
<td>Ergometrine maleate 0.2 mg per tablet, oral ingestion tablet</td>
<td>[G02AB03or]</td>
<td>HSC, BHC, MHT, CHC, DH</td>
</tr>
<tr>
<td>Methylergometrine maleate 0.2 mg/ml, in 1 ml, injection ampoule</td>
<td>[G02AB01inj]</td>
<td>BHC, CHC, DH</td>
</tr>
<tr>
<td>Misoprostol 200 mcg per tablet, oral ingestion tablet</td>
<td>[G02AD20or]</td>
<td>PPH</td>
</tr>
<tr>
<td>Misoprostol 25 mcg per tablet, vaginal tablet</td>
<td>[G02AD06vg]</td>
<td>PPH</td>
</tr>
</tbody>
</table>

#### G02B — CONTRACEPTIVES FOR TOPICAL USE

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Condom with and without nonoxinol 1 pce per piece, topical</td>
<td>[G02BX01]</td>
<td>HP, HSC, BHC, MHT, CHC, DH</td>
</tr>
<tr>
<td>Intrauterine device with copper 1 pce per piece, vaginal intrauterine device</td>
<td>[G02BA02]</td>
<td>BHC*, CHC, DH</td>
</tr>
</tbody>
</table>

#### G02C — OTHER GYNECOLOGICALS

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nifedipine 10 mg per tablet, oral ingestion tablet</td>
<td>[G02CA04or]</td>
<td>BHC*, MHT*, CHC, DH</td>
</tr>
<tr>
<td>Nifedipine 20 mg per capsule, oral ingestion capsule</td>
<td>[G02CA04or]</td>
<td>CHC, DH</td>
</tr>
</tbody>
</table>

### G03 — SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM

#### G03A — HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethinylestradiol 0.035 mg + norethisterone 1 mg per tablet, oral ingestion tablet</td>
<td>[G03AA05or]</td>
<td>HP, HSC, BHC, MHT, CHC, DH</td>
</tr>
<tr>
<td>Ethinylestradiol 0.03 mg + levonorgestrel 0.15 mg per tablet, oral ingestion tablet</td>
<td>[G03AA07or]</td>
<td>HP, HSC, BHC, MHT, CHC, DH</td>
</tr>
<tr>
<td>Ethinylestradiol 0.03 mg + norgestrel 0.3 mg per tablet, oral ingestion tablet</td>
<td>[G03AA06or]</td>
<td>HP, HSC, BHC, MHT, CHC, DH</td>
</tr>
<tr>
<td>Ethinylestradiol 0.05 mg + levonorgestrel 0.25 mg per tablet, oral ingestion tablet</td>
<td>[G03AA07or]</td>
<td>HP, HSC, BHC, MHT, CHC, DH</td>
</tr>
<tr>
<td>Levonorgestrel 0.03 mg per tablet, oral ingestion tablet</td>
<td>[G03AC03or]</td>
<td>HP, HSC, BHC, MHT, CHC, DH</td>
</tr>
<tr>
<td>Medroxyprogesterone acetate depot 150 mg/ml, in 1 ml vial, injection solution</td>
<td>[G03AC06inj]</td>
<td>HP, HSC, BHC, MHT, CHC, DH</td>
</tr>
</tbody>
</table>

---

EML - Version of July 2014
Norgestrel 0.075 mg per tablet, oral ingestion tablet [G03AC10or]  
HP, HSC, BHC, MHT, CHC, DH  
DH, PH, RH  
FP

G03C—ESTROGENS
Ethinylestradiol 0.01 mg per tablet, oral ingestion tablet [G03CA01or]  
HP, BHC, CHC, DH  
RH
Ethinylestradiol 0.05 mg per tablet, oral ingestion tablet [G03CA01or]  
HP, BHC, CHC, DH  
RH

G03D—PROGESTOGENS
Norethisterone 5 mg per tablet, oral ingestion tablet [G03DC02or]

G03G—GONADOTROPINS AND OTHER OVULATION STIMULANTS
Clomifene 50 mg per tablet, oral ingestion tablet [G03GB02or]  
RH

H—SYSTEMIC HORMONAL PREPARATIONS, EXCLUDING SEX HORMONES AND INSULINS

H01—PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES

H01B—POSTERIOR PITUITARY LOBE HORMONES
Oxytocin 10 IU/ml, in 1 ml ampoule, injection solution [H01BB02inj]  
HSC, BHC, MHT, CHC, DH  
DH, PH, RH

H02—CORTICOSTEROIDS FOR SYSTEMIC USE

H02A—CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN
Hydrocortisone sodium succinate 100 mg per vial, injection vial [H02AB09inj]  
HSC, BHC, MHT, CHC, DH  
DH, PH, RH
Prednisolone 5 mg per tablet, oral ingestion tablet [H02AB06or]  
DH  
DH, PH, RH

H03—THYROID THERAPY

H03A—THYROID PREPARATIONS
Levothyroxine 0.05 mg per tablet, oral ingestion tablet [H03AA01or]  
RH
Levothyroxine 0.1 mg per tablet, oral ingestion tablet [H03AA01or]  
RH

H03B—ANTITHYROID PREPARATIONS

EML - Version of July 2014
Carbimazole 5 mg per tablet, oral ingestion tablet [H03BB01or]  

**H03C—IODINE THERAPY**

Iodine 200 mg per capsule, oral ingestion capsule [H03CA20or]  
Iodine 480 mg/ml, in 0.5 ml ampoule, oral ampoule [H03CA20or]  
Iodine 540 mg/ml, in 0.57 ml bottle, oral solution [H03CA20or]  

**J—ANTI-INFECTIVES FOR SYSTEMIC USE**

**J01—ANTIBACTERIALS FOR SYSTEMIC USE**

**J01A—TETRACYCLINES**

Doxycycline 100 mg per capsule, oral ingestion capsule [J01AA02or]  

**J01B—AMPHENICOLS**

Chloramphenicol 125 mg/5 ml, in 100 ml bottle, oral syrup [J01BA01or]  
Chloramphenicol 1 g per vial, injection powder [J01BA01inj]  
Chloramphenicol 250 mg per capsule, oral ingestion capsule [J01BA01or]  
Chloramphenicol 500 mg per vial, injection powder [J01BA01inj]  

**J01C—BETA-LACTAM ANTIBACTERIALS, PENICILLINS**

Amoxicillin 125 mg/5 ml, in 60 ml bottle, oral ingestion suspension [J01CA04or]  
Amoxicillin 125 mg + clavulanic acid 31.25 mg/5 ml, in 60 ml bottle, oral ingestion suspension [J01CR02or]  
Amoxicillin 250 mg/5 ml, in 60 ml bottle, oral ingestion suspension [J01CA04or]  
Amoxicillin 250 mg per tablet, oral ingestion tablet [J01CA04or]  
Amoxicillin 500 mg per tablet, oral ingestion tablet [J01CA04or]  
Amoxicillin 500 mg + clavulanic acid 125 mg (co-amoxiclav) per tablet, oral ingestion tablet [J01CR02or]  
Ampicillin 1 g per vial, injection powder [J01CA01inj]  
Ampicillin 500 mg per vial, injection powder [J01CA01inj]  
Cloxacillin 250 mg per capsule, oral ingestion capsule [J01CF02or]  
Cloxacillin 500 mg per capsule, oral ingestion capsule [J01CF02or]  
Penicillin benzyl (peni G crystal) 1 MU per vial, injection vial [J01CE01inj]  
Penicillin benzyl (peni G crystal) 5 MU per vial, injection vial [J01CE01inj]  
Penicillin benzyl 0.5 MU + penicillin procaine 1.5 MU per vial, injection vial [J01CE09inj]  
Penicillin benzyl 1 MU + penicillin procaine 3 MU per vial, injection vial [J01CE09inj]  

EML - Version of July 2014
**J01D—OTHER BETA-LACTAM ANTIBACTERIALS**

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>Formulation</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Penicillin benzyl 2 MU + penicillin procaine 6 MU per vial, injection vial</td>
<td>J01CE09inj</td>
<td>BHC*, CHC, DH</td>
</tr>
<tr>
<td>Penicillin benzyl benzathine 1.2 MU per vial, injection vial</td>
<td>J01CE08inj</td>
<td>HSC*, BHC*, MHT*, CHC, DH</td>
</tr>
<tr>
<td>Penicillin benzyl benzathine 2.4 MU per vial, injection vial</td>
<td>J01CE08inj</td>
<td>HSC*, BHC*, MHT*, CHC, DH</td>
</tr>
<tr>
<td>Penicillin benzyl procaine 2 MU per vial, injection vial</td>
<td>J01CE09inj</td>
<td>BHC*, MHT*, CHC, DH</td>
</tr>
<tr>
<td>Penicillin benzyl procaine 4 MU per vial, injection vial</td>
<td>J01CE09inj</td>
<td>BHC*, MHT*, CHC, DH</td>
</tr>
<tr>
<td>Penicillin V (phenoxymethylpenicillin) 250 mg/5 ml, in 100 ml bottle, oral ingestion suspension</td>
<td>J01CE02or</td>
<td>HSC, BHC, MHT, CHC, DH</td>
</tr>
<tr>
<td>Penicillin V (phenoxymethylpenicillin) 250 mg per tablet, oral ingestion tablet</td>
<td>J01CE02or</td>
<td>HSC, BHC, MHT, CHC, DH</td>
</tr>
<tr>
<td>Penicillin V (phenoxymethylpenicillin) 500 mg per tablet, oral ingestion tablet</td>
<td>J01CE02or</td>
<td>HSC, BHC, MHT, CHC, DH</td>
</tr>
</tbody>
</table>

**J01E—SULFONAMIDES AND TRIMETHOPRIM**

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>Formulation</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sulfamethoxazole 100 mg + trimethoprim 20 mg (co-trimoxazole) per tablet, oral ingestion tablet</td>
<td>J01EE01or</td>
<td>HP, BHC, MHT, CHC, DH</td>
</tr>
<tr>
<td>Sulfamethoxazole 200 mg + trimethoprim 40 mg (co-trimoxazole)/5 ml, in 50 ml bottle, oral ingestion suspension</td>
<td>J01EE01or</td>
<td>HP, BHC, MHT, CHC, DH</td>
</tr>
<tr>
<td>Sulfamethoxazole 400 mg + trimethoprim 80 mg (co-trimoxazole) per tablet, oral ingestion tablet</td>
<td>J01EE01or</td>
<td>HP, BHC, MHT, CHC, DH</td>
</tr>
</tbody>
</table>

**J01F—MACROLIDES, LINCOSAMIDES, AND STREPTOGRAMINS**

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>Formulation</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Azithromycin 250 mg per capsule, oral ingestion capsule</td>
<td>J01FA10or</td>
<td>DH</td>
</tr>
<tr>
<td>Azithromycin 500 mg per capsule, oral ingestion capsule</td>
<td>J01FA10or</td>
<td>DH</td>
</tr>
<tr>
<td>Clindamycin 150 mg per capsule, oral ingestion capsule</td>
<td>J01FF01or</td>
<td>CHC, DH</td>
</tr>
<tr>
<td>Clindamycin 900 mg + dextrose 5% in 50 ml, parenteral infusion</td>
<td>[J01FF01inj]</td>
<td>CHC, DH</td>
</tr>
<tr>
<td>Erythromycin (base) 125 mg/5 ml, in 60 ml, oral ingestion suspension</td>
<td>J01FA01or</td>
<td>HSC, BHC, MHT, CHC, DH</td>
</tr>
<tr>
<td>Erythromycin (ethylsuccinate) 200 mg per tablet, oral ingestion tablet</td>
<td>J01FA01or</td>
<td>HSC, BHC, MHT, CHC, DH</td>
</tr>
<tr>
<td>Erythromycin (ethylsuccinate) 400 mg per tablet, oral ingestion tablet</td>
<td>J01FA01or</td>
<td>HSC, BHC, MHT, CHC, DH</td>
</tr>
<tr>
<td>Erythromycin stearate 250 mg per tablet, oral ingestion tablet</td>
<td>J01FA01or</td>
<td>HSC, BHC, MHT, CHC, DH</td>
</tr>
<tr>
<td>Erythromycin stearate 500 mg per tablet, oral ingestion tablet</td>
<td>J01FA01or</td>
<td>HSC, BHC, MHT, CHC, DH</td>
</tr>
</tbody>
</table>

**J01G—AMINOGLYCOSIDE ANTIBACTERIALS**

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>Formulation</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amikacin 500 mg/ml, in 2 ml vial, injection vial</td>
<td>J01GB06inj</td>
<td>DH, PH, RH</td>
</tr>
<tr>
<td>Gentamicin 10 mg/ml, in 2 ml ampoule, injection solution</td>
<td>J01GB03inj</td>
<td>HSC, BHC, MHT, CHC, DH</td>
</tr>
<tr>
<td>Gentamicin 20 mg/ml, in 2 ml ampoule, injection solution</td>
<td>J01GB03inj</td>
<td>HSC, BHC, MHT, CHC, DH</td>
</tr>
<tr>
<td>Gentamicin 40 mg/ml, in 2 ml ampoule, injection solution</td>
<td>J01GB03inj</td>
<td>HSC, BHC, MHT, CHC, DH</td>
</tr>
<tr>
<td>Streptomycin 1 g per vial, injection vial</td>
<td>J01GA01inj</td>
<td>HSC, BHC, MHT, CHC, DH</td>
</tr>
<tr>
<td>Streptomycin 5 g per vial, injection vial</td>
<td>J01GA01inj</td>
<td>HSC, BHC, MHT, CHC, DH</td>
</tr>
</tbody>
</table>
J01M—QUINOLONE ANTIBACTERIALS

Ciprofloxacin 250 mg per tablet, oral ingestion tablet [J01MA02or]

Ciprofloxacin 2 mg/ml, in 50 ml ampoule, infusion solution [J01MA02inj]

Ciprofloxacin 500 mg per tablet, oral ingestion tablet [J01MA02or]

Moxifloxacin 400 mg per tablet, oral ingestion tablet [J01MA14or]

Nalidixic acid 250 mg per tablet, oral ingestion tablet [J01MB02or]

Nalidixic acid 2 mg/ml, in 50 ml ampoule, infusion solution [J01MB02inj]

Nalidixic acid 500 mg per tablet, oral ingestion tablet [J01MB02or]

J01X—OTHER ANTIBACTERIALS

Metronidazole 5 mg/ml, in 100 ml bottle, oral ingestion solution [J01X00inj]

Nitrofurantoin 100 mg per tablet, oral ingestion tablet [J01XE01or]

J02—ANTIMYCOBACTERIALS

J02A—ANTIMYCOBACTERICIANS FOR TREATMENT OF TUBERCULOSIS

Capreomycin 1 g per vial, injection powder [J04AB30inj]

Cycloserine 250 mg per capsule, oral ingestion capsule [J04AB01or]

Ethambutol (E) 275 mg + isoniazid (H) 75 mg + pyrazinamide (Z) 400 mg + rifampicin (R) 150 mg (RHZE)

per tablet, oral capsule or tablet [J04AM06or]

Ethambutol (EMB) 100 mg per tablet, oral ingestion tablet [J04AK02or]

Ethambutol (EMB) 400 mg per tablet, oral ingestion tablet [J04AK02or]

Ethambutol 400 mg + isoniazid 75 mg (EH) per tablet, oral ingestion tablet [J04AM03or]

Ethionamide 250 mg per tablet, oral ingestion tablet [J04AD03or]

Isoniazid (INH) 100 mg per tablet, oral ingestion tablet [J04AC01or]

Isoniazid (INH) 300 mg per tablet, oral ingestion tablet [J04AC01or]

Isoniazid (INH) 50 mg per tablet, oral ingestion tablet [J04AC01or]

Para-aminosalicylic acid (PAS) 4 g per sachet, oral ingestion granules [J04AA01or]

Pyrazinamide (PZA) 150 mg per tablet, oral ingestion tablet [J04AK01or]
<table>
<thead>
<tr>
<th>Medicine</th>
<th>Dosage</th>
<th>Formulation</th>
<th>Reference Numbers</th>
<th>Conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pyrazinamide (PZA)</td>
<td>400 mg per tablet</td>
<td>Oral ingestion tablet [J04AK01or]</td>
<td>HSC, BHC, CHC, DH</td>
<td>DH, PH, RH</td>
</tr>
<tr>
<td>Pyrazinamide (PZA)</td>
<td>500 mg per tablet</td>
<td>Oral ingestion tablet [J04AK01or]</td>
<td>HSC, BHC, CHC, DH</td>
<td>DH, PH, RH</td>
</tr>
<tr>
<td>Rifampicin</td>
<td>150 mg per tablet</td>
<td>Oral ingestion tablet [J04AB02or]</td>
<td>HSC, BHC, CHC, DH</td>
<td>DH, PH, RH</td>
</tr>
<tr>
<td>Rifampicin</td>
<td>300 mg per tablet</td>
<td>Oral ingestion tablet [J04AB02or]</td>
<td>HSC, MHT, BHC, CHC, DH</td>
<td>DH, PH, RH</td>
</tr>
<tr>
<td>Rifampicin + Isoniazid</td>
<td>75 mg per tablet</td>
<td>Oral ingestion tablet [J04AM02or]</td>
<td>HSC, BHC, CHC, DH</td>
<td>DH, PH, RH</td>
</tr>
<tr>
<td>Rifampicin + Isoniazid + Ethambutol</td>
<td>275 mg</td>
<td>Oral ingestion tablet [J04AM07or]</td>
<td>HSC, BHC, CHC, DH</td>
<td>DH, PH, RH</td>
</tr>
<tr>
<td>Rifampicin + Pyrazinamide + Ethambutol</td>
<td>400 mg</td>
<td>Oral ingestion tablet or capsule [J04AM06or]</td>
<td>NTP</td>
<td></td>
</tr>
<tr>
<td>Rifampicin + Isoniazid + Ethambutol</td>
<td>275 mg</td>
<td>Oral ingestion tablet [J04AM03or]</td>
<td>HSC, BHC, CHC, DH</td>
<td>DH, PH, RH</td>
</tr>
<tr>
<td>Streptomycin (STM)</td>
<td>1 g per vial</td>
<td>Injection vial [J04AB31inj]</td>
<td>HSC, BHC, CHC, DH</td>
<td>PH, RH</td>
</tr>
<tr>
<td>Clofazimine (CLO)</td>
<td>100 mg per capsule</td>
<td>Oral ingestion capsule [J04BA01or]</td>
<td>PH, RH</td>
<td>NLP</td>
</tr>
<tr>
<td>Clofazimine (CLO)</td>
<td>50 mg per capsule</td>
<td>Oral ingestion capsule [J04BA01or]</td>
<td>PH, RH</td>
<td>NLP</td>
</tr>
<tr>
<td>Dapsone (DDS)</td>
<td>100 mg per tablet</td>
<td>Oral ingestion tablet [J04BA02or]</td>
<td>PH, RH</td>
<td>NLP</td>
</tr>
<tr>
<td>Dapsone (DDS)</td>
<td>25 mg per tablet</td>
<td>Oral ingestion tablet [J04BA02or]</td>
<td>PH, RH</td>
<td>NLP</td>
</tr>
<tr>
<td>Dapsone (DDS)</td>
<td>50 mg per tablet</td>
<td>Oral ingestion tablet [J04BA02or]</td>
<td>PH, RH</td>
<td>NLP</td>
</tr>
<tr>
<td>Rifampicin + Dapsone + Clofazimine</td>
<td>50 mg</td>
<td>Oral ingestion tablet [J04BA01or]</td>
<td>PH, RH</td>
<td>NLP</td>
</tr>
<tr>
<td>Rifampicin + Dapsone + Clofazimine</td>
<td>100 mg</td>
<td>Oral ingestion tablet [J04BA01or]</td>
<td>PH, RH</td>
<td>NLP</td>
</tr>
</tbody>
</table>

**J04B—MEDICINES FOR TREATMENT OF LEPRA**

<table>
<thead>
<tr>
<th>Medicine</th>
<th>Dosage</th>
<th>Formulation</th>
<th>Reference Numbers</th>
<th>Conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abacavir (ABC)</td>
<td>300 mg per tablet</td>
<td>Oral ingestion tablet [J05AF06or]</td>
<td>HIV</td>
<td></td>
</tr>
<tr>
<td>Atazanavir + Ritonavir</td>
<td>100 mg per tablet</td>
<td>Oral ingestion tablet [J05AR12or]</td>
<td>HIV</td>
<td></td>
</tr>
<tr>
<td>Delavirdine</td>
<td>200 mg per tablet</td>
<td>Oral ingestion tablet [J05AG02or]</td>
<td>HIV</td>
<td></td>
</tr>
<tr>
<td>Efavirenz (EFV)</td>
<td>100 mg per capsule</td>
<td>Oral ingestion capsule [J05AG03or]</td>
<td>HIV</td>
<td></td>
</tr>
<tr>
<td>Efavirenz (EFV)</td>
<td>150 mg/5 ml</td>
<td>Oral ingestion liquid [J05AG03or]</td>
<td>HIV</td>
<td></td>
</tr>
<tr>
<td>Efavirenz (EFV)</td>
<td>200 mg per capsule</td>
<td>Oral ingestion capsule [J05AG03or]</td>
<td>HIV</td>
<td></td>
</tr>
<tr>
<td>Efavirenz (EFV)</td>
<td>50 mg per capsule</td>
<td>Oral ingestion capsule [J05AG03or]</td>
<td>HIV</td>
<td></td>
</tr>
<tr>
<td>Efavirenz (EFV)</td>
<td>600 mg per tablet</td>
<td>Oral ingestion tablet [J05AG03or]</td>
<td>HIV</td>
<td></td>
</tr>
<tr>
<td>Efavirenz + Emtricitabine</td>
<td>200 mg + Tenofovir</td>
<td>300 mg</td>
<td>Oral ingestion tablet [J05AR06or]</td>
<td>HIV</td>
</tr>
<tr>
<td>Emtricitabine (FTC)</td>
<td>200 mg per capsule</td>
<td>Oral ingestion capsule [J05AF09or]</td>
<td>HIV</td>
<td></td>
</tr>
<tr>
<td>Emtricitabine (FTC)</td>
<td>50 mg/5 ml</td>
<td>Oral ingestion liquid [J05AF09or]</td>
<td>HIV</td>
<td></td>
</tr>
<tr>
<td>Emtricitabine + Tenofovir</td>
<td>300 mg</td>
<td>Oral ingestion tablet [J05AR03or]</td>
<td>HIV</td>
<td></td>
</tr>
<tr>
<td>Enfuvirtide</td>
<td>108 mg per vial</td>
<td>Injection powder [J05AX07inj]</td>
<td>HIV</td>
<td></td>
</tr>
<tr>
<td>Entecavir</td>
<td>0.5 mg per tablet</td>
<td>Oral ingestion tablet [J05AF10or]</td>
<td>HIV</td>
<td></td>
</tr>
</tbody>
</table>
EML  -  Version of July 2014

Etravirine 25 mg per tablet, oral ingestion tablet [J05AF10or] HIV
Fosamprenavir 700 mg + ritonavir 100 mg (FPV/r) per tablet, oral ingestion tablet [J05AR13or]
Indinavir (IDV) 200 mg per capsule, oral ingestion capsule [J05AE02or] HIV
Indinavir (IDV) 333 mg per capsule, oral ingestion capsule [J05AE02or] HIV
Indinavir (IDV) 400 mg per capsule, oral ingestion capsule [J05AE02or] HIV
Indinavir 800 mg + ritonavir 100 mg (IDV/r) per tablet, oral ingestion tablet [J05AR11or] HIV
Lamivudine (3TC) 100 mg per tablet, oral ingestion tablet [J05AF05or] HIV
Lamivudine (3TC) 150 mg per tablet, oral ingestion tablet [J05AF05or] HIV
Lamivudine (3TC) 300 mg per tablet, oral ingestion tablet [J05AF05or] HIV
Lamivudine (3TC) 50 mg/5 ml, oral ingestion suspension [J05AF05or] HIV
Lamivudine 150 mg + nevirapine 200 mg + zidovudine 300 mg (AZT/3TC/NVP) per tablet, oral ingestion tablet [J05AR05or] HIV
Lamivudine 40 mg + stavudine 10 mg (d4T/3TC)/5 ml, oral solution [J05AR09or]
Lamivudine 150 mg + zidovudine 300 mg (AZT/3TC) per tablet, oral ingestion tablet [J05AR01or] HIV
Lopinavir 133.3 mg + ritonavir 33.3 mg (LPV/r) per capsule, oral ingestion capsule [J05AR10or] HIV
Lopinavir 200 mg + ritonavir 50 mg (LPV/r) per capsule, oral ingestion capsule [J05AR10or] HIV
Lopinavir 400 mg + ritonavir 100 mg (LPV/r)/5 ml, oral ingestion liquid [J05AR10or] HIV
Maraviroc 150 mg per tablet, oral ingestion tablet [J05AX09or] HIV
Maraviroc 300 mg per tablet, oral ingestion tablet [J05AX09or] HIV
Nelfinavir (NFV) 200 mg/5 ml, oral ingestion suspension [J05AE04or] HIV
Nelfinavir (NFV) 250 mg per tablet, oral ingestion tablet [J05AE04or] HIV
Nelfinavir (NFV) 50 mg/g in 144 g pack, oral ingestion powder [J05AE04or] HIV
Nelfinavir (NFV) 625 mg per tablet, oral ingestion tablet [J05AE04or] HIV
Raltegravir 400 mg per tablet, oral ingestion tablet [J05AX08or] HIV
Ritonavir (RTV) 100 mg per tablet, oral ingestion tablet [J05AE03or] HIV
Ritonavir (RTV) 400 mg/5 ml, oral ingestion liquid [J05AE03or] HIV
Saquinavir (SQV) 200 mg per capsule, oral ingestion capsule [J05AE01or] HIV
Saquinavir 200 mg + ritonavir 500 mg (SQV/r) per tablet, oral ingestion tablet [J05AR08or] HIV
Stavudine 30 mg + lamivudine 150 mg (d4T/3TC) per tablet, oral ingestion tablet [J05AR09or] HIV
Stavudine 40 mg + lamivudine 150 mg (d4T/3TC) per tablet, oral ingestion tablet [J05AR09or] HIV
Zidovudine (AZT) 10 mg/ml, in 20 ml vial, injection solution [J05AF01inj] HIV
Zidovudine (AZT) 100 mg per capsule, oral ingestion capsule [J05AF01or] HIV
Zidovudine (AZT) 250 mg per capsule or tablet, oral ingestion capsule or tablet [J05AF01or] HIV
Zidovudine (AZT) 300 mg per tablet, oral ingestion tablet [J05AF01or] HIV
Zidovudine (AZT) 50 mg/5 ml, oral ingestion suspension [J05AF01or] HIV

J06—IMMUNE SERA AND IMMUNOGLOBULINS

J06A—IMMUNE SERA
Diphtheria antitoxin 10,000 IU per vial, injection vial [J06AA01inj] PH, RH
Diphtheria antitoxin 20,000 IU per vial, injection vial [J06AA01inj] 
Rabies antitoxin 150 mg/ml, in 1 ml, injection vial [J06AA06inj] 
Scorpion antivenom in 5 ml, injection vial [J06AA20inj] 

J06B—IMMUNOGLOBULINS 
Anti-D immunoglobulin (human) 250 mcg per dose, in single dose vial, injection vial [J06BB01inj] 
Antitetanus immunoglobulin 250 IU/ml, in 1 ml ampoule, injection solution [J06BB02inj] 
Antitetanus immunoglobulin 1,500 IU/ml, in 1 ml ampoule, injection solution [J06BB02inj] 
Antitetanus immunoglobulin 3,000 IU/ml, in 1 ml ampoule, injection solution [J06BB02inj] 
Antitetanus Immunoglobulin 500 IU/ml, in 1 ml ampoule, injection solution [J06BB02inj] 

J07—VACCINES 

J07A—BACTERIAL VACCINES 
Diphtheria, pertussis, tetanus vaccine 20 doses per vial, injection vial [J07AF30inj] 
Pneumococcal conjugated vaccine 23-valent single dose per vial, injection vial [J07AL02inj] 
Pneumococcal conjugated vaccine 7-valent single dose per vial, injection vial [J07AL02inj] 
Tetanus toxoid vaccine 20 doses per vial, injection vial [J07AM01inj] 
Tuberculosis vaccine (BCG) with diluent 20 doses per vial, injection vial [J07AN01inj] 

J07B—VIRAL VACCINES 
Hepatitis B monovalent vaccine single dose (HepB) per milliliter, per vial, injection solution [J07BC01inj] 
Measles diluent 10 doses per vial, injection vial [J07BD01inj] 
Measles vaccine 10 doses per vial, injection vial [J07BD01inj] 
Oral polio vaccine–bivalent (OPV-B) 20 doses per vial, oral vaccine [J07BF01or] 
Oral polio vaccine–monovalent (OPV-M) 20 doses per vial, oral vaccine [J07BF01or] 
Oral polio vaccine–trivalent (OPV-T) 20 doses per vial, oral vaccine [J07BF02or] 
Rota virus monovalent/pentavalent single or double dose in two vials, oral vaccine [J07BH01or] 
Rubella vaccine, live attenuated in single dose, injection vial [J07BJ01or] 

J07C—BACTERIAL AND VIRAL VACCINES, COMBINED 
Diphtheria, pertussis, tetanus, HepB, Hib vaccine 20 doses per vial, injection vial [J07CA03inj] 
Diphtheria, pertussis, tetanus, hepatitis B vaccine 10 doses per milliliter, injection vial [J07CA52inj] 

L—ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01—ANTINEOPLASTIC AGENTS

L01B—ANTIMETABOLITES
Fluorouracil 5% topical ointment [L01BC02] RH

L02—ENDOCRINE THERAPY

L02A—HORMONES AND RELATED AGENTS
Ethinyloestradiol 0.05 mg per tablet, oral ingestion tablet [L02AA03or] RH

L04—IMMUNOSUPPRESSANTS

L04A—IMMUNOSUPPRESSANTS
Ciclosporin (cyclosporine) 100 mg/5 ml, oral ingestion solution [L04AD01or] HIV

M—MUSCULOSKELETAL SYSTEM

M01—ANTI-INFLAMMATORY AND ANTIRHEUMATIC PRODUCTS

M01A—ANTI-INFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NONSTEROIDS
Diclofenac (sodium or potassium) 50 mg per tablet, oral ingestion tablet [M01AB05or] CHC, DH, PH, RH
Diclofenac (sodium or potassium) 25 mg/ml, in 3 ml ampoule, injection solution [M01AB05inj] HSC, BHC, MHT, CHC, DH, PH, RH
Ibuprofen 200 mg per tablet, oral ingestion tablet [M01AE01or] HSC, BHC, MHT, CHC, DH
Ibuprofen 400 mg per tablet, oral ingestion tablet [M01AE01or] HSC, BHC, MHT, CHC, DH, PH, RH

M01C—SPECIFIC ANTIRHEUMATIC AGENTS
Methotrexate 2.5 mg per tablet, oral ingestion tablet [M01CX01or] CHC, DH
Penicillamine 125 mg per tablet, oral ingestion tablet [M01CC01or] HSC, BHC, MHT, CHC, DH
Penicillamine 250 mg per tablet, oral ingestion tablet [M01CC01or] DH, PH, RH
Sulfasalazine 500 mg per tablet, oral ingestion tablet [M01CX02or] DH, PH, RH
M03—MUSCLE RELAXANTS

M03A—MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS

Suxamethonium 50 mg/ml, in 2 ml ampoule, injection solution [M03AB01inj]

PH, RH

M04—ANTIGOUT PREPARATIONS

M04A—ANTIGOUT PREPARATIONS

Allopurinol 100 mg per tablet, oral ingestion tablet [M04AA01or]

Colchicine 0.5 mg per tablet, oral ingestion tablet [M04AC01or]

RH

N—NERVOUS SYSTEM

N01—ANESTHETICS

N01A—ANESTHETICS, GENERAL

Halothane 250 ml, per bottle, inhalation solution [N01AB01]

RH

Isoflurane in 250 ml, gas [N01AB06]

Ketamine 50 mg/ml, in 10 ml vial, injection solution [N01AX03inj]

CHC, DH

Propofol 10 mg/ml, in 100 ml ampoule, infusion solution [N01AX10inj]

RH

Propofol 10 mg/ml, in 20 ml, infusion solution [N01AX10inj]

PH, RH

Thiopental sodium 1 g per vial, injection powder [N01AF03inj]

RH

Thiopental sodium 500 mg per vial, injection powder [N01AF03inj]

RH

N01B—ANESTHETICS, LOCAL

Adrenalin 0.0005% + lidocaine 1% injection solution [N01BB52inj]

CHC, DH

Adrenalin 0.0005% + lidocaine 2% in 50 ml vial, injection solution [N01BB52inj]

RH

Adrenalin 0.00125% + lidocaine dental 1% injection solution [N01BB52inj]

MHT, CHC, DH

Adrenalin 0.00125% + lidocaine dental 2% injection solution [N01BB52inj]

MHT, CHC, DH

Bupivacaine 0.25% in 10 ml ampoule, injection solution [N01BB01inj]

RH

Bupivacaine 0.5% in 10 ml ampoule, injection solution [N01BB01inj]

PH, RH

Glucose 7.5% + lidocaine 5% (lidocaine spinal) injection solution [N01BB52inj]

DH

Lidocaine 1% in 2 ml, injection vial [N01BB02inj]

HSC, BHC, MHT, CHC, DH

DH, PH, RH
Lidocaine 2% in 2 ml ampoule, injection solution [N01BB02inj]  

N02—ANALGESICS

N02A—OPIOIDS

Morphine (sulfate, hydrochloride) 10 mg/ml, in 1 ml ampoule, injection solution [N02AA01inj]  
Pethidine 100 mg per tablet, oral ingestion tablet [N02AB02or]  
Pethidine 50 mg/ml, injection solution [N02AB02inj]  
Tramadol 50 mg per capsule, oral ingestion capsule [N02AX02or]  
Tramadol 50 mg/ml, in 2 ml, injection solution [N02AX02inj]

N02B—OTHER ANALGESICS AND ANTIPYRETICS

Acetylsalicylic acid (aspirin) 100 mg per tablet, oral ingestion tablet [N02BA01or]  
Acetylsalicylic acid (aspirin) 300 mg per tablet, oral ingestion tablet [N02BA01or]  
Acetylsalicylic acid (aspirin) 325 mg per tablet, oral ingestion tablet [N02BA01or]  
Paracetamol (acetaminophen) 100 mg/ml, in 15 ml bottle, oral ingestion drop [N02BE01or]  
Paracetamol (acetaminophen) 100 mg per tablet, oral ingestion tablet [N02BE01or]  
Paracetamol (acetaminophen) 120 mg/5 ml, in 60 ml bottle, oral syrup [N02BE01or]  
Paracetamol (acetaminophen) 125 mg per suppository, rectal suppository [N02BE01rec]  
Paracetamol (acetaminophen) 325 mg per tablet, oral ingestion tablet [N02BE01or]  
Paracetamol (acetaminophen) 500 mg per tablet, oral ingestion tablet [N02BE01or]

N02C—ANTIMIGRAINE PREPARATIONS

Ergotamine 1 mg per tablet, oral ingestion tablet [N02CA02or]

N03—ANTIEPILEPTICS

N03A—ANTIEPILEPTICS

Carbamazepine 100 mg per tablet, oral ingestion tablet [N03AF01or]  
Carbamazepine 200 mg per tablet, oral ingestion tablet [N03AF01or]  
Ethosuximide 250 mg/5 ml, oral syrup [N03AD01or]  
Ethosuximide 250 mg per capsule, oral ingestion capsule [N03AD01or]  
Magnesium sulfate 500 mg/ml, in 10 ml ampoule, injection solution [N03AX31inj]  
Magnesium sulfate 500 mg/ml, in 20 ml ampoule, injection solution [N03AX31inj]
Magnesium sulfate 500 mg/ml, in 2 ml ampoule, injection solution [N03AX31inj]  
Phenobarbital 100 mg/ml, in 2 ml, injection solution [N03AA02inj]  
Phenobarbital 100 mg per tablet, oral ingestion tablet [N03AA02or]  
Phenobarbital 15 mg per tablet, oral ingestion tablet [N03AA02or]  
Phenobarbital 25 mg per tablet, oral ingestion tablet [N03AA02or]  
Phenobarbital 30 mg per tablet, oral ingestion tablet [N03AA02or]  
Phenobarbital 50 mg/ml, in 5 ml, injection solution [N03AA02inj]  
Phenobarbital 50 mg per tablet, oral ingestion tablet [N03AA02or]  
Valproic acid (sodium valproate) 200 mg per tablet, oral ingestion tablet [N03AG01or]  
Valproic acid (sodium valproate) 500 mg per tablet, oral ingestion tablet [N03AG01or]

N04—ANTI-PARKINSON MEDICINES

N04A—ANTICHOLINERGIC AGENTS

Biperiden 2 mg per tablet, oral ingestion tablet [N04AA02or]  
Biperiden 5 mg/ml, in 1 ml ampoule, injection solution [N04AA02inj]  
Trihexyphenidyl 2 mg per tablet, oral ingestion tablet [N04AA01or]

N04B—DOPAMINERGIC AGENTS

Bromocriptine mesylate 2.5 mg per tablet, oral ingestion tablet [N04BC01or]  
Carbidopa 10 mg + levodopa 100 mg per tablet, oral ingestion tablet [N04BA02or]  
Carbidopa 25 mg + levodopa 250 mg per tablet, oral ingestion tablet [N04BA02or]

N05—PSYCHOLEPTICS

N05A—ANTIPSYCHOTICS

Chlorpromazine 25 mg per tablet, oral ingestion tablet [N05AA01or]  
Chlorpromazine 100 mg per tablet, oral ingestion tablet [N05AA01or]  
Chlorpromazine 25 mg/ml, in 2 ml ampoule, injection solution [N05AA01inj]  
Fluphenazine (oily) 1 mg/ml, in 1 ml ampoule, injection solution [N05AB02inj]  
Haloperidol 2 mg per tablet, oral ingestion tablet [N05AD01or]  
Haloperidol 5 mg/ml, in 1 ml, injection solution [N05AD01inj]  
Haloperidol 5 mg per tablet, oral ingestion tablet [N05AD01or]

N05B—ANXIOLYTICS

Alprazolam 0.5 mg per tablet, oral ingestion tablet [N05BA12or]
Chlordiazepoxide 10 mg per tablet, oral ingestion tablet [N05BA02or]
Diazepam 10 mg per tablet, oral ingestion tablet [N05BA01or]
Diazepam 2 mg per tablet, oral ingestion tablet [N05BA01or]
Diazepam 5 mg/ml, in 2 ml, injection solution [N05BA01inj]
Diazepam 5 mg per tablet, oral ingestion tablet [N05BA01or]

N05C—HYPNOTICS AND SEDATIVES
Midazolam 1 mg/ml, in 1 ml ampoule, injection solution [N05CD08inj]

N06—PSYCHOANALEPTICS

N06A—ANTIDEPRESSANTS
Amitriptyline 25 mg per tablet, oral ingestion tablet [N06AA09or]
Clomipramine 25 mg per tablet, oral ingestion tablet [N06AA04or]
Clomipramine 50 mg per tablet, oral ingestion tablet [N06AA04or]
Fluoxetine 20 mg per capsule, oral ingestion capsule [N06AB03or]
Imipramine 10 mg per tablet, oral ingestion tablet [N06AA02or]
Imipramine 25 mg per tablet, oral ingestion tablet [N06AA02or]
Nortriptyline 10 mg per tablet, oral ingestion tablet [N06AA10or]

N07—OTHER NERVOUS SYSTEM MEDICINES

N07A—PARASYMPATHOMIMETICS
Neostigmine bromide 15 mg per tablet, oral ingestion tablet [N07AA01or]
Neostigmine methylsulfate 0.5 mg/ml, in 10 ml, injection solution [N07AA01inj]

N07B—MEDICINES USED IN ADDICTIVE DISORDERS
Buprenorphine 2 mg per tablet, oral ingestion tablet [N07BC01or]
Buprenorphine 8 mg per tablet, oral ingestion tablet [N07BC01or]
Methadone 10 mg/ml per milliliter, in 1 ml ampoule, injection solution [N07BC02inj]
Methadone 10 mg/ml, oral solution [N07BC02or]
Methadone 10 mg per tablet, oral ingestion tablet [N07BC02or]
Methadone 5 mg/ml, oral solution [N07BC02or]
Methadone 5 mg per tablet, oral ingestion tablet [N07BC02or]
Opium tincture 10% oral solution [N07BC59or]
## P—ANTIPARASITIC PRODUCTS, INSECTICIDES, AND REPELLENTS

### P01—ANTIPROTOZOALS

#### P01A—AGENTS AGAINST AMEBIASIS AND OTHER PROTOZOAAL DISEASES

| Metronidazole 200 mg/5 ml, in 60 ml bottle, oral ingestion suspension [P01AB01or] | HSC, BHC, MHT, CHC, DH | DH, PH, RH |
| Metronidazole 200 mg per tablet, oral ingestion tablet [P01AB01or] | HSC, BHC, MHT, CHC, DH | DH, PH, RH |
| Metronidazole 250 mg per tablet, oral ingestion tablet [P01AB01or] | HSC, BHC, MHT, CHC, DH | DH, PH, RH |
| Metronidazole 400 mg per tablet, oral ingestion tablet [P01AB01or] | HSC, BHC, MHT, CHC, DH | DH, PH, RH |
| Metronidazole 500 mg per tablet, oral ingestion tablet [P01AB01or] | HSC, BHC, MHT, CHC, DH | DH, RH, PH, |

#### P01B—ANTIMALARIALS

| Artemether oily 20 mg/ml, injection solution [P01BE02inj] | PH, RH | NMLP |
| Artemether oily 40 mg/ml, injection solution [P01BE02inj] | PH, RH | NMLP |
| Artemether oily 80 mg/ml, injection solution [P01BE02inj] | PH, RH | NMLP |
| Artesunate 100 mg + pyrimethamine 25 mg + sulfadoxine 500 mg per tablet (co-blister), oral ingestion | HSC, BHC, MHT, CHC, DH | DH, PH, RH |
| Artesunate 300 mg + pyrimethamine 50 mg + sulfadoxine 1,000 mg per tablet, oral ingestion tablet [P01BF04or] | BHC, CHC, DH | DH, PH, RH |
| Artesunate 50 mg + pyrimethamine 25 mg + sulfadoxine 500 mg per tablet, oral ingestion tablet [P01BF04or] | HSC, BHC, MHT, CHC, DH | DH, PH, RH |
| Artesunate 600 mg + pyrimethamine 75 mg + sulfadoxine 1,500 mg per tablet, oral ingestion tablet [P01BF04or] | BHC, CHC, DH | DH, PH, RH |
| Chloroquine (base) 150 mg per tablet, oral ingestion tablet [P01BA01or] | HP, HSC, BHC, MHT, CHC, DH | DH, PH, RH |
| Chloroquine (base) 50 mg/ml, in 60 ml, oral syrup [P01BA01or] | HP, HSC, BHC, MHT, CHC, DH | DH, PH, RH |
| Primaquine 15 mg per tablet, oral ingestion tablet [P01BA03or] | CHC, DH | DH, RH, PH, |
| Primaquine 7.5 mg per tablet, oral ingestion tablet [P01BA03or] | CHC, DH | DH, RH, PH, |
| Quinine dihydrochloride 300 mg/ml, in 2 ml ampoule, injection solution [P01BC01inj] | CHC, DH | DH, PH, RH |
| Quinine sulfate 300 mg per tablet, oral ingestion tablet [P01BC01or] | HSC, BHC, MHT, CHC, DH | DH, PH, RH |

### P01C—AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS

| Meglumine antimoniate 30% in 5 ml ampoule, injection solution [P01CB01inj] | CHC, DH | DH, PH, RH |
| Sodium stibogluconate 100 mg/ml, injection solution [P01CB02inj] | CHC, DH | DH, PH, RH |

### P02—ANTHELMINTICS

#### P02C—ANTINEMATODAL AGENTS
Albendazole 200 mg per tablet, oral chewable tablet [P02CA03or]  DH  DH, PH, RH
Albendazole 400 mg per tablet, oral chewable tablet [P02CA03or]  DH  DH, PH, RH
Mebendazole 100 mg per tablet, oral chewable tablet [P02CA01or]  HSC, BHC, MHT, CHC, DH  DH, PH, RH

P02D—ANTICESTODALS
Niclosamide 500 mg per tablet, oral ingestion chewable tablet [P02DA01or]  BHC, CHC, DH  DH, PH, RH,

P03—ECTOPARASITICIDES, INCLUDING SCABICIDES, INSECTICIDES, AND REPELLENTS

P03A—ECTOPARASITICIDES, INCLUDING SCABICIDES
Benzoic acid 6% + salicylic acid 3% topical ointment [P03AX01]  HSC, BHC, MHT, CHC, DH  DH, PH, RH
Benzyl benzoate 25% in 60 ml bottle, topical lotion [P03AX01]  BHC, CHC, DH,  DH, PH, RH,
Lindane 1% topical shampoo [P03AB02]  HSC, BHC, MHT, CHC, DH  DH, PH, RH
Permethrin 1% in 60 ml bottle, topical lotion [P03AC04]  BHC, CHC, DH,  DH
Permethrin 5% in 30 g tube, topical cream [P03AC04]  BHC, CHC, DH,  DH, PH, RH,

R—RESPIRATORY SYSTEM

R01—NASAL PREPARATIONS

R01A—DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
Naphazoline 0.05% in 10 ml bottle, nasal drop [R01AA08]  PH, RH
Sodium chloride 0.65% in 10 ml, nasal drop [R01AX30]  BHC, CHC, DH,  DH, PH, RH,

R03—MEDICINES FOR OBSTRUCTIVE AIRWAY DISEASES

R03A—ADRENERGICS, INHALANTS
Salbutamol 0.1 mg per dose, in 200-dose bottle, inhalation solution [R03AC02]  HSC, BHC, MHT, CHC, DH  DH, PH, RH
Salbutamol 5 mg/ml, nebulizer solution [R03AC02]  HSC, BHC, MHT, CHC, DH  DH, PH, RH

R03B—OTHER MEDICINES FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS
Beclometasone dipropionate 250 mcg per dose, inhalation aerosol [R03BA01]  PH, RH
Beclometasone dipropionate 50 mcg per dose, inhalation aerosol [R03BA01]  PH, RH
R03C—ADRENERGICS FOR SYSTEMIC USE
Salbutamol 0.05 mg/ml, in 5 ml ampoule, injection ampoule [R03CC02inj] RH
Salbutamol 0.5 mg/ml, in 1 ml ampoule, injection ampoule or vial [R03CC02inj] RH
Salbutamol 2 mg/5 ml, in 60 ml bottle, oral syrup [R03CC02or] HSC, BHC, MHT, CHC, DH DH, PH, RH
Salbutamol 2 mg per tablet, oral ingestion tablet [R03CC02or] PH, RH
Salbutamol 4 mg per tablet, oral ingestion tablet [R03CC02or] HSC, BHC, MHT, CHC, DH DH, PH, RH

R03D—OTHER SYSTEMIC MEDICINES FOR OBSTRUCTIVE AIRWAY DISEASES
Aminophylline 100 mg per tablet, oral ingestion tablet [R03DA05or] RH
Aminophylline 25 mg/ml, in 10 ml ampoule, injection solution [R03DA05inj] RH

R06—ANTIHISTAMINES FOR SYSTEMIC USE
R06A—ANTIHISTAMINES FOR SYSTEMIC USE
Chlorphenamine maleate 10 mg/ml, in 1 ml, injection solution [R06AB04inj] HSC, BHC, MHT, CHC, DH DH, PH, RH
Chlorphenamine maleate 4 mg per tablet, oral ingestion tablet [R06AB04or] HP, HSC, BHC, MHT, CHC, DH DH, PH, RH
Dimenhydrinate 50 mg per tablet, oral ingestion tablet [R06AA52or] RH
Diphenhydramine chloride 25 mg per tablet, oral ingestion tablet [R06AA02or] RH
Diphenhydramine chloride 50 mg per tablet, oral ingestion tablet [R06AA02or] RH
Diphenhydramine chloride 5 mg/5 ml, in 60 ml, oral syrup [R06AA02or] RH
Diphenhydramine teoclate 50 mg per tablet, oral ingestion tablet [R06AA02or] RH
Promethazine 25 mg/ml, in 2 ml ampoule, injection solution [R06AD02inj] RH
Promethazine 25 mg per tablet, oral ingestion tablet [R06AD02or] RH
Promethazine 5 mg/5 ml, oral syrup [R06AD02or] RH

S—SENSORY ORGANS
S01—OPHTHALMOLOGICALS
S01A—EYE ANTI-INFECTIVES
Aciclovir 3% in 5 g tube, ophthalmic ointment [S01AD03] PH, RH
Chloramphenicol 0.5% in 2.5 ml bottle, ophthalmic drop [S01AA01] PH, RH
Gentamicin 0.3% in 5 ml bottle, ophthalmic drop [S01AA11] RH
Neomycin sulfate 0.5% in 15 g tube, topical cream [S01AA03] DH, DH, PH, RH,
Sulfacetamide 10% in 15 ml bottle, ophthalmic drop [S01AB04]  RH
Sulfacetamide 20% in 15 ml bottle, ophthalmic drop [S01AB04]  RH
Tetracycline 1% in 5g, ophthalmic ointment [S01AA09]  HP, HSC, BHC, MHT, CHC, DH, PH, RH

S01B—EYE ANTI-INFLAMMATORY AGENTS
Prednisolone 0.5% in 5 ml bottle, ophthalmic drop [S01BA04]  RH
Prednisolone 1% in 5 ml bottle, ophthalmic drop [S01BA04]  RH

S01E—ANTIGLAUCOMA PREPARATIONS AND MIOTICS
Acetazolamide 250 mg per tablet, oral ingestion tablet [S01EC01or]  RH
Pilocarpine 2% in 15 ml bottle, ophthalmic drop [S01EB01]  RH
Pilocarpine 4% in 15 ml bottle, ophthalmic drop [S01EB01]  RH
Timolol 0.25% in 5 ml bottle, ophthalmic drop [S01ED01]  RH
Timolol 0.5% in 5 ml bottle, ophthalmic drop [S01ED01]  RH

S01F—MYDRIATICS AND CYCLOPLEGICS
Atropine sulfate 0.1% in 5 ml bottle, ophthalmic drop [S01FA01]  RH
Atropine sulfate 0.5% in 5 ml bottle, ophthalmic drop [S01FA01]  RH
Atropine Sulfate 1% in 5 ml bottle, ophthalmic drop [S01FA01]  RH
Tropicamide 0.5% in 15 ml bottle, ophthalmic drop [S01FA06]  RH
Tropicamide 1% in 3 ml bottle, ophthalmic drop [S01FA06]  RH

S01H—EYE LOCAL ANESTHETICS
Tetracaine 0.5% in 15 ml bottle, ophthalmic drop [S01HA03]  CHC, DH

S02—OTOLOGICALS

S02A—EAR ANTI-INFECTIVES
Boric acid + glycerin 5% (glycerin boric) otic liquid [S02AA03]  RH

V—VARIOUS

V03—ALL OTHER THERAPEUTIC PRODUCTS
**V03A—ALL OTHER THERAPEUTIC PRODUCTS**

Acetylcysteine 200 mg/ml, in 10 ml ampoule, injection solution [V03AB23or] RH

Atropine sulfate 1 mg/ml, in 1 ml ampoule, injection solution [V03AB29or] CHC, DH DH, PH, RH

Deferoxamine mesylate 500 mg per vial, injection powder [V03AC01inj] RH

Diamercaprol (BAL) 100 mg/ml, in 3 ml ampoule, injection solution [V03AB09inj] RH

Diamercaprol (BAL) 50 mg/ml, in 2 ml ampoule, injection solution [V03AB09inj] RH

Flumazenil 0.1 mg/ml, in 10 ml, injection solution [V03AB25inj] DH DH, PH, RH

Methylene blue (methylthioninium) 10 mg/ml, in 10 ml ampoule, injection solution [V03AB17inj] RH

Naloxone 400 mcg/ml, in 1 ml, injection solution [V03AB15or] CHC, DH DH, PH, RH

Oxygen inhalation gas [V03AN01] HSC, BHC, CHC, DH DH, PH, RH

Potassium iodide 60 mg per tablet, oral ingestion tablet [V03AB21or] PH, RH

Pralidoxime 500 mg/ml, injection solution [V03AB04inj] PH, RH

Protamine sulfate 10 mg/ml, in 5 ml ampoule, injection solution [V03AB14inj] PH, RH

**V04—DIAGNOSTIC AGENTS**

**V04C—OTHER DIAGNOSTIC AGENTS**

Tuberculin purified protein derivative 100 IU/ml, injection solvent [V04CF01] PH, RH

Tuberculin purified protein derivative 10 IU/ml, injection solvent [V04CF01] DH, PH, RH

**V07—ALL OTHER NONTHERAPEUTIC PRODUCTS**

**V07A—ALL OTHER NONTHERAPEUTIC PRODUCTS**

Water for injection per milliliter, in 10 ml ampoule, injection solution [V07AB01inj] HP, HSC, BHC, MHT, CHC, DH DH, PH, RH

Water for injection per milliliter, in 5 ml ampoule, injection solution [V07AB01inj] HP, HSC, BHC, MHT, CHC, DH DH, PH, RH

**V08—CONTRAST MEDIA**

**V08A—X-RAY CONTRAST MEDIA, IODINATED**

Diatrizoic acid (amidotrizoate) 420 mg/ml, injection solution [V08AA01inj] RH

Diatrizoic acid meglumine 66% + diatrizoic acid sodium 10% (Urografin76) injection solution [V08AA01inj] RH

**V08B—X-RAY CONTRAST MEDIA, NON-IODINATED**

Barium sulfate 30% parenteral aqueous solution [V08A01] PH, RH
V99—UNCLASSIFIED

V99A—DENTAL AND DISPENSARY ITEMS
Vaseline [V99AB00] Disp.
Essential Medicines List Alphabetical Index

NOTE: the numbers in front of the medicine names indicate the line number and do not have any other meaning.

A

Abacavir (ABC) 300 mg per tablet, oral ingestion tablet [J05AF06or] *See: National HIV/AIDS Program List*

Acetazolamide 250 mg per tablet, oral ingestion tablet [S01EC01or]

Acetylcysteine 200 mg/ml, in 10 ml ampoule, injection ampoule [V03AB23inj]

Acetylsalicylic acid (aspirin) 100 mg per tablet, oral ingestion tablet [B01AC06or]

Acetylsalicylic acid (aspirin) 300 mg per tablet, oral ingestion tablet [N02BA01or]

Acetylsalicylic acid (aspirin) 325 mg per tablet, oral ingestion tablet [N02BA01or]

Acetylsalicylic acid (aspirin) 325 mg per tablet, oral ingestion tablet [B01AC06or]

Acetylsalicylic acid (aspirin) 500 mg per tablet, oral ingestion tablet [N02BA01or]

Aciclovir 3% in 5 g tube, ophthalmic ointment [S01AD03]

Activated charcoal 1 g per tablet, oral ingestion tablet [A07BA01or]

Activated charcoal 500 mg per tablet, oral ingestion tablet [A07BA01or]

Adrenalin 0.0005% + lidocaine 1% injection solution [N01BB52inj]

Adrenalin 0.00125% + lidocaine dental 1% injection solution [N01BB52inj]

Adrenalin 0.00125% + lidocaine dental 2% injection solution [N01BB52inj]

Albendazole 200 mg per tablet, oral chewable tablet [P02CA03or]

Albendazole 400 mg per tablet, oral chewable tablet [P02CA03or]

Allopurinol 100 mg per tablet, oral ingestion tablet [M04AA01or]

Alprazolam 0.5 mg per tablet, oral ingestion tablet [N05BA12or]

Aluminium hydroxide 120 mg + magnesium trisilicate 250 mg per tablet, oral ingestion tablet [A02AD01or]

Aluminium hydroxide 200 mg + magnesium hydroxide 200 mg per tablet, oral chewable tablet [A02AD01or]

Aluminium hydroxide 225 mg + magnesium hydroxide 200 mg/5 ml, in 200 ml bottle, oral ingestion suspension [A02AD01or]

Amikacin 500 mg/ml, in 2 ml vial, injection vial [J01GB06inj]

Aminophylline 100 mg per tablet, oral ingestion tablet [R03DA05or]

Aminophylline 25 mg/ml, in 10 ml ampoule, injection solution [R03DA05inj]

 Amitriptyline 25 mg per tablet, oral ingestion tablet [N06AA09or]

Amlodipine 5 mg per tablet, oral ingestion tablet [C08CA01or]

Amoxicillin 125 mg/5 ml, in 60 ml bottle, oral ingestion suspension [J01CA04or]

Amoxicillin 125 mg + clavulanic acid 31.25 mg/5 ml, in 60 ml bottle, oral ingestion suspension [J01CR02or]

Amoxicillin 250 mg/5 ml, in 60 ml bottle, oral ingestion suspension [J01CA04or]

Amoxicillin 250 mg per tablet, oral ingestion tablet [J01CA04or]

Amoxicillin 500 mg per tablet, oral ingestion tablet [J01CA04or]

Amoxicillin 500 mg + clavulanic acid 125 mg (co-amoxiclav) per tablet, oral ingestion tablet [J01CR02or]

Ampicillin 1 g per vial, injection powder [J01CA01inj]

Ampicillin 500 mg per vial, injection powder [J01CA01inj]

Anti-D immunoglobulin (human) 250 mcg per dose, in single-dose vial, injection vial [J06BB01inj]

Antitetanus immunoglobulin 250 IU/ml, in 1 ml ampoule, injection solution [J06BB02inj]

Antitetanus immunoglobulin 1,500 IU/ml, in 1 ml ampoule, injection solution [J06BB02inj]

Antitetanus immunoglobulin 3,000 IU/ml, in 1 ml ampoule, injection solution [J06BB02inj]

Antitetanus immunoglobulin 500 IU/ml, in 1 ml ampoule, injection solution [J06BB02inj]

Artemether (oily) 20 mg/ml, injection solution [P01BE02inj] *See: National Malaria and Leishmania Control Program List*

Artemether (oily) 40 mg/ml, injection solution [P01BE02inj] *See: National Malaria and Leishmania Control Program List*

Artemether (oily) 80 mg/ml, injection solution [P01BE02inj] *See: National Malaria and Leishmania Control Program List*

Artesunate 100 mg + pyrimethamine 25 mg + sulfadoxine 500 mg per tablet (co-blisters), oral ingestion tablet [P01BF04or] *See: National Malaria and Leishmania Control Program List*

Artesunate 300 mg + pyrimethamine 50 mg + sulfadoxine 1,000 mg per tablet, oral ingestion tablet [P01BF04or] *See: National Malaria and Leishmania Control Program List*

Artesunate 50 mg + pyrimethamine 25 mg + sulfadoxine 500 mg per tablet, oral ingestion tablet [P01BF04or] *See: National Malaria and Leishmania Control Program List*

Artesunate 600 mg + pyrimethamine 75 mg + sulfadoxine 1,500 mg per tablet, oral ingestion tablet [P01BF04or] *See: National Malaria and Leishmania Control Program List*

Atazanavir 300 mg + ritonavir 100 mg (ATV/RTV) per tablet, oral ingestion tablet [J05AR12or] *See: National
HIV/AIDS Program List*

Atenolol 25 mg per tablet, oral ingestion tablet [C07AB03or]
Atenolol 50 mg per tablet, oral ingestion tablet [C07AB03or]
Atenolol 100 mg per tablet, oral ingestion tablet [C07AB03or]
Atorvastatin 20 mg per tablet, oral ingestion tablet [C10AA05or]
Atropine sulfate 0.5% in 5 ml bottle, ophthalmic drop [S01FA01]
Atropine sulfate 1% in 5 ml bottle, ophthalmic drop [S01FA01]
Atropine sulfate 1 mg/ml, in 1 ml ampoule, injection solution [A03BA01inj]
Atropine sulfate 1 mg/ml, in 1 ml ampoule, injection solution [V03BA29inj]
Atropine sulfate 1 mg per tablet, oral ingestion tablet [A03BA01or]
Azithromycin 250 mg per capsule, oral ingestion capsule [J01FA10or]
Azithromycin 500 mg per capsule, oral ingestion capsule [J01FA10or]

Atropine sulfate 0.5% in 5 ml bottle, ophthalmic drop [S01FA01]
Atropine sulfate 1% in 5 ml bottle, ophthalmic drop [S01FA01]
Atropine sulfate 1 mg/ml, in 1 ml ampoule, injection solution [A03BA01inj]
Atropine sulfate 1 mg/ml, in 1 ml ampoule, injection solution [V03BA29inj]
Atropine sulfate 1 mg per tablet, oral ingestion tablet [A03BA01or]
Azithromycin 250 mg per capsule, oral ingestion capsule [J01FA10or]
Azithromycin 500 mg per capsule, oral ingestion capsule [J01FA10or]

Bacitracin 500 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]
Bacitracin 6000 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]
Bacitracin 6000 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]
Bacitracin 6000 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]
Bacitracin 6000 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]
Bacitracin 6000 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]
Bacitracin 6000 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]
Bacitracin 6000 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]

Bacitracin 500 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]
Bacitracin 6000 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]
Bacitracin 6000 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]
Bacitracin 6000 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]
Bacitracin 6000 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]
Bacitracin 6000 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]
Bacitracin 6000 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]
Bacitracin 6000 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]

Bacitracin 500 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]
Bacitracin 6000 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]
Bacitracin 6000 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]
Bacitracin 6000 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]
Bacitracin 6000 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]
Bacitracin 6000 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]
Bacitracin 6000 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]
Bacitracin 6000 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]

Bacitracin 500 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]
Bacitracin 6000 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]
Bacitracin 6000 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]
Bacitracin 6000 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]
Bacitracin 6000 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]
Bacitracin 6000 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]
Bacitracin 6000 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]
Bacitracin 6000 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]

Bacitracin 500 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]
Bacitracin 6000 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]
Bacitracin 6000 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]
Bacitracin 6000 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]
Bacitracin 6000 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]
Bacitracin 6000 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]
Bacitracin 6000 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]
Bacitracin 6000 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]

Bacitracin 500 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]
Bacitracin 6000 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]
Bacitracin 6000 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]
Bacitracin 6000 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]
Bacitracin 6000 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]
Bacitracin 6000 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]
Bacitracin 6000 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]
Bacitracin 6000 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]
Chlorpromazine 100 mg per tablet, oral ingestion tablet [N05AA01or]
Chlorpromazine 25 mg/ml, in 2 ml ampoule, injection solution [N05AA01inj]
Colecalciferol (vit D3) 600,000 IU/ml, injection solution [A11CC05inj]
Ciclosporin (cyclosporine) 100 mg/5 ml, oral ingestion solution [L04AD01or]
Ciprofloxacin 250 mg per tablet, oral ingestion tablet [J01MA02or]
Ciprofloxacin 250 mg, in 50 ml ampoule, infusion solution [J01MA02inj]
Ciprofloxacin 500 mg per tablet, oral ingestion tablet [J01MA02or]
Clindamycin 150 mg per capsule, oral ingestion capsule [J01FF01or]
Clindamycin 900 mg + dextrose 5% in 50 ml, parenteral infusion [J01FF01inj]
Clofazimine (CLO) 100 mg per capsule, oral ingestion capsule [J04BA01or] *See: National Leprosy Program List*
Clofazimine (CLO) 50 mg per capsule, oral ingestion capsule [J04BA01or] *See: National Leprosy Program List*
Clomifene 50 mg per tablet, oral ingestion tablet [G03GB02or]
Clomipramine 25 mg per tablet, oral ingestion tablet [N06AA04or]
Clomipramine 50 mg per tablet, oral ingestion tablet [N06AA04or]
Cloxacillin 250 mg per capsule, oral ingestion capsule [J01CF02or]
Cloxacillin 500 mg per capsule, oral ingestion capsule [J01CF02or]
Cloxacillin 500 mg per vial, injection powder [J01CF02inj]
Coagulation factor II, VII, IX, X per ampoule, injection solution [B02BD01inj]
Coagulation factor VIII per ampoule, injection solution [B02BD02inj]
Coal tar 5% in 100 g bottle, topical lotion [D05AA01]
Colchicine 0.5 mg per tablet, oral ingestion tablet [M04AC01or]
Colestyramine (cholestyramine) 4 g per sachet, oral ingestion powder [C10AC01or]
Condom with and without nonoxinol 1 pce per piece, topical [G02BX01] *See: National Family Planning Program List*
Cycloserine 250 mg per capsule, oral ingestion capsule [J04AB01or] *See: National Tuberculosis Program List*
Dapsone (DDS) 100 mg per tablet, oral ingestion tablet [J04BA02or] *See: National Leprosy Program List*
Dapsone (DDS) 25 mg per tablet, oral ingestion tablet [J04BA02or] *See: National Leprosy Program List*
Dapsone (DDS) 50 mg per tablet, oral ingestion tablet [J04BA02or] *See: National Leprosy Program List*
Deferoxamine mesylate 500 mg per vial, injection powder [V03AC01inj]
Delavirdine 200 mg per tablet, oral ingestion tablet [J05AG02or]
Dextrans 70 6% injection solution [B05AA05inj]
Diatrizoic acid (amidotrizoate) 420 mg/ml, injection solution [V08AA01inj]
Diatrizoic acid meglumine 66% + diatrizoic acid sodium 10% (Urografin 76) injection solution [V08AA01inj]
Diazepam 10 mg per tablet, oral ingestion tablet [N05BA01or]
Diazepam 2 mg per tablet, oral ingestion tablet [N05BA01or]
Diazepam 5 mg/ml in 2 ml, injection solution [N05BA01inj]
Diazepam 5 mg per tablet, oral ingestion tablet [N05BA01or]
Diclofenac (sodium or potassium) 50 mg per tablet, oral ingestion tablet [M01AB05or]
Diclofenac (sodium or potassium) 25 mg/ml, in 3 ml ampoule, injection solution [M01AB05inj]
Digoxin 0.25 mg/ml, in 2 ml ampoule, injection solution [C01AA05inj]
Digoxin 0.25 mg per tablet, oral ingestion tablet [C01AA05or]
Dimethylnitrate 50 mg per tablet, oral ingestion tablet [R06AA52or]
Dimercaprol (BAL) 100 mg/ml, in 3 ml ampoule, injection solution [V03AB09inj]
Dimercaprol (BAL) 50 mg/ml, in 2 ml ampoule, injection solution [V03AB09inj]
Diphenhydramine chloride 25 mg per tablet, oral ingestion tablet [R06AA02or]
Diphenhydramine chloride 50 mg per tablet, oral ingestion tablet [R06AA02or]
Diphenhydramine chloride 5 mg/5 ml, in 60 ml, oral syrup [R06AA02or]
Diphenhydramine teoclate 50 mg per tablet, oral ingestion tablet [R06AA02or]
Diphtheria antitoxin 10,000 IU per vial, injection vial [J06AA01inj]
Diphtheria antitoxin 20,000 IU per vial, injection vial [J06AA01inj]
Diphtheria, pertussis, tetanus vaccine 20 doses per vial, injection vial [J07AF30inj]
Diphtheria, pertussis, tetanus, hepatitis B vaccine 10 doses per milliliter, injection vial [J07CA52inj]
Dopamine 40 mg/ml, in 5 ml vial, injection solution [C01CA04inj]
Doxycycline 100 mg per capsule, oral ingestion capsule [J01AA02or]
Efavirenz (EFV) 100 mg per capsule, oral ingestion capsule [J05AG03or] *See: National HIV/AIDS Program List*
Efavirenz (EFV) 150 mg, in 5 ml, oral ingestion liquid [J05AG03or] *See: National HIV/AIDS Program List*
Efavirenz (EFV) 200 mg per capsule, oral ingestion capsule [J05AG03or] *See: National HIV/AIDS Program List*
Efavirenz (EFV) 50 mg per capsule, oral ingestion capsule [J05AG03or] *See: National HIV/AIDS Program List*
Efavirenz (EFV) 60 mg per capsule, oral ingestion capsule [J05AG03or] *See: National HIV/AIDS Program List*
<table>
<thead>
<tr>
<th>Medicine</th>
<th>Dosage/Description</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Efavirenz 600 mg + emtricitabine 200 mg + tenofovir 300 mg (EFV/FTC/TDF) per tablet, oral ingestion tablet</td>
<td>[J05AR06or] <em>See: National HIV/AIDS Program List</em></td>
<td></td>
</tr>
<tr>
<td>Emtricitabine (FTC) 200 mg per capsule, oral ingestion capsule [J05AF09or]</td>
<td><em>See: National HIV/AIDS Program List</em></td>
<td></td>
</tr>
<tr>
<td>Emtricitabine (FTC) 50 mg/5 ml, oral ingestion liquid [J05AF09or]</td>
<td><em>See: National HIV/AIDS Program List</em></td>
<td></td>
</tr>
<tr>
<td>Emtricitabine 200 mg + tenofovir 300 mg (FTC/TDF) per tablet, oral ingestion tablet [J05AR03or]</td>
<td><em>See: National HIV/AIDS Program List</em></td>
<td></td>
</tr>
<tr>
<td>Enalapril 10 mg per tablet, oral ingestion tablet [C09AA02or]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Enfuvirtide 108 mg per vial, injection powder [J05AX07or]</td>
<td><em>See: National HIV/AIDS Program List</em></td>
<td></td>
</tr>
<tr>
<td>Enoxaparin 100 mg/ml, in 1 ml ampoule, injection solution [B01AB05inj]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Entecavir 25 mg per tablet, oral ingestion tablet [J05AF09or]</td>
<td><em>See: National HIV/AIDS Program List</em></td>
<td></td>
</tr>
<tr>
<td>Etravirine 0.1 mg/ml, in 1 ml ampoule, injection solution [C01CA24inj]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epinephrine (adrenaline) 0.1% in 1 ml ampoule, injection solution [G02AB03inj]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ergometrine maleate 0.2 mg/ml, injection solution [G02AB03inj]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ergometrine maleate 0.2 mg per tablet, oral ingestion tablet [G02AB03or]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ergotamine 1 mg per tablet, oral ingestion tablet [N02CA02or]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erythromycin (base) 125 mg/5 ml, in 60 ml, oral ingestion suspension [J01FA01or]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erythromycin (ethylsuccinate) 200 mg per tablet, oral ingestion tablet [J01FA01or]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erythromycin (ethylsuccinate) 400 mg per tablet, oral ingestion tablet [J01FA01or]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erythromycin stearate 250 mg per tablet, oral ingestion tablet [J01FA01or]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erythromycin stearate 500 mg per tablet, oral ingestion tablet [J01FA01or]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethambutol (EMB) 100 mg per tablet, oral ingestion tablet [J04AM02or]</td>
<td><em>See: National Tuberculosis Program List</em></td>
<td></td>
</tr>
<tr>
<td>Ethambutol (EMB) 400 mg per tablet, oral ingestion tablet [J04AK02or]</td>
<td><em>See: National Tuberculosis Program List</em></td>
<td></td>
</tr>
<tr>
<td>Ethambutol 400 mg + isoniazid 75 mg (EH) per tablet, oral ingestion tablet [J04AM03or]</td>
<td><em>See: National Tuberculosis Program List</em></td>
<td></td>
</tr>
<tr>
<td>Ethambutol 275 mg (E) + isoniazid 75 mg (H) + pyrazinamide 400 mg (Z) + rifampicin (R) 150 mg (RHZE) per tablet, oral ingestion tablet [J04AM06or]</td>
<td><em>See: National Tuberculosis Program List</em></td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol 0.01 mg per tablet, oral ingestion tablet [G03CA01or]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol 0.035 mg + norethisterone 1 mg per tablet, oral ingestion tablet [G03AA05or]</td>
<td><em>See: National Family Planning Program List</em></td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol 0.03 mg + levonorgestrel 0.15 mg per tablet, oral ingestion tablet [G03CA01or]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol 0.03 mg + norgestrel 0.3 mg per tablet, oral ingestion tablet [G03AA06or]</td>
<td><em>See: National Family Planning Program List</em></td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol 0.05 mg per tablet, oral ingestion tablet [L02AA03or]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol 0.05 mg per tablet, oral ingestion tablet [G03CA01or]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol 0.05 mg + levonorgestrel 0.25 mg per tablet, oral ingestion tablet [G03AA07or]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethionamide 250 mg per tablet, oral ingestion tablet [J04AD03or]</td>
<td><em>See: National Tuberculosis Program List</em></td>
<td></td>
</tr>
<tr>
<td>Ethosuximide 250 mg/5 ml, oral syrup [N03AD01or]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethosuximide 250 mg per capsule, oral ingestion capsule [N03AD01or]</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**F**

<table>
<thead>
<tr>
<th>Medicine</th>
<th>Dosage/Description</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fenofibrate 200 mg per capsule, oral ingestion capsule [C10AB05or]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ferrous sulfate 125 mg/5 ml, in 120 ml, oral ingestion liquid [B03AA07or]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ferrous sulfate 60 mg per tablet, oral ingestion tablet [B03AA07or]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ferrous sulfate 60 mg + folic acid (vit B9) 0.4 mg per tablet, oral ingestion tablet [B03AD03or]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flumazenil 0.1 mg/ml, in 10 ml, injection solution [V03AB25inj]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluorouracil 5% topical ointment [L01BC02]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluoxetine 20 mg per capsule, oral ingestion capsule [N06AB03or]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluphenazine (oily) 1 mg/ml, in 1 ml ampoule, injection solution [N05AB02inj]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Folic acid (vit B9) 1 mg per tablet, oral ingestion tablet [A11HA11or]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Folic acid (vit B9) 1 mg per tablet, oral ingestion tablet [B03BB01or]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Folic acid (vit B9) 5 mg per tablet, oral ingestion tablet [A11HA11or]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Folic acid (vit B9) 5 mg per tablet, oral ingestion tablet [B03BB01or]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fosamprenavir 700 mg + ritonavir 100 mg (FPV/r) per tablet, oral ingestion tablet [J05AR13or]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Furazolidone 100 mg per tablet, oral ingestion tablet [G01AX06or]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Furazolidone 125 mg/5 ml, in 60 ml, oral syrup [G01AX06or]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Furosemide 10 mg/ml, in 2 ml ampoule, injection solution [C03CA01inj]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Furosemide 20 mg per tablet, oral ingestion tablet [C03CA01or]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Furosemide 40 mg per tablet, oral ingestion tablet [C03CA01or]</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**G**

<table>
<thead>
<tr>
<th>Medicine</th>
<th>Dosage/Description</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gentamicin 0.3% in 5 ml bottle, ophthalmic drop [S01AA11]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gentamicin 10 mg/ml, in 2 ml ampoule, injection solution [J01GB03inj]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gentamicin 20 mg/ml, in 2 ml ampoule, injection solution [J01GB03inj]</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

EML - Version of July 2014
Gentamicin 40 mg/ml, in 2 ml ampoule, injection solution [J01GB03inj]
Glibenclamide 5 mg per tablet, oral ingestion tablet [A10BB01or]
Glucose 10% in 1,000 ml bottle, injection solution [B05CX01inj]
Glucose 10% in 500 ml bottle, injection solution [B05CX01inj]
Glucose 4% + sodium chloride 0.18% in 1,000 ml bottle, injection solution [B05BB02inj]
Glucose 4% + sodium chloride 0.18% in 500 ml bottle, injection solution [B05BB02inj]
Glucose 5% in 1,000 ml bottle, injection solution [B05CX01inj]
Glucose 5% in 500 ml bottle, injection solution [B05CX01inj]
Glucose 5% + sodium chloride 0.9% in 1,000 ml bottle, injection solution [B05BB02inj]
Glucose 5% + sodium chloride 0.9% in 500 ml bottle, injection solution [B05BB02inj]
Glucose 50% injection solution [B05BA03inj]
Glucose 7.5% + lidocaine 5% (lidocaine spinal) injection solution [N01BB52inj]
Glyceryl trinitrate (nitroglycerine) 0.5 mg per tablet, sublingual-oral tablet [C01DA02or]
Griseofulvin 125 mg per tablet, oral ingestion tablet [D01BA01or]
Griseofulvin 250 mg per tablet, oral ingestion tablet [D01BA01or]
Griseofulvin 500 mg per tablet, oral ingestion tablet [D01BA01or]

Haloperidol 2 mg per tablet, oral ingestion tablet [N05AD01or]
Haloperidol 5 mg/ml, in 1 ml, injection solution [N05AD01inj]
Haloperidol 5 mg per tablet, oral ingestion tablet [N05AD01or]
Halothane 250 ml per bottle, inhalation solution [N01AB01inj]
Heparin 1,000 IU/ml, in 5 ml ampoule, injection solution [B01AB01inj]
Heparin 2,500 IU/ml, in 5 ml ampoule, injection solution [B01AB01inj]
Heparin 5,000 IU/ml, in 1 ml ampoule, injection solution [B01AB01inj]
Hepatitis B monovalent vaccine single dose (HepB) per milliliter Per vial, injection solution [J07BC01inj]
Hydralazine 20 mg/ml, in 2 ml, injection solution [C02DB01inj]
Hydralazine 25 mg per tablet, oral ingestion tablet [C02DB02or]
Hydralazine 50 mg per tablet, oral ingestion tablet [C02DB02or]
Hydrochlorothiazide 25 mg per tablet, oral ingestion tablet [C03AA03or]
Hydrochlorothiazide 50 mg per tablet, oral ingestion tablet [C03AA03or]
Hydrocortisone acetate 1% in 15 g tube, topical cream [D07AA02]
Hydrocortisone sodium succinate 100 mg per vial, injection vial [H02AB09inj]
Hydrogen peroxide 6% topical solution [D08AX01]
Hydroxocobalamine (vit B12) 0.5 mg/ml, in 1 ml ampoule, injection solution [B03BA03inj]
Hydroxocobalamine (vit B12) 1 mg/ml, in 1 ml ampoule, injection solution [B03BA03inj]
Hyoscine (butylbromide, hydrobromide) 10 mg per tablet, oral ingestion tablet [A03BB01or]
Hyoscine (butylbromide, hydrobromide) 20 mg/ml, in 1 ml ampoule, injection solution [A03BB01inj]

Ibuprofen 200 mg per tablet, oral ingestion tablet [M01AE01or]
Ibuprofen 400 mg per tablet, oral ingestion tablet [M01AE01or]
Imipramine 10 mg per tablet, oral ingestion tablet [N06AA02or]
Imipramine 25 mg per tablet, oral ingestion tablet [N06AA02or]
Indinavir (IDV) 200 mg per capsule, oral ingestion capsule [J05AE02or] *See: National HIV/AIDS Program List*
Indinavir (IDV) 333 mg per capsule, oral ingestion capsule [J05AE02or] *See: National HIV/AIDS Program List*
Indinavir (IDV) 400 mg per capsule, oral ingestion capsule [J05AE02or] *See: National HIV/AIDS Program List*
Indinavir 800 mg + ritonavir 100 mg (IDV/r) per tablet, oral ingestion tablet [J05AR11] *See: National HIV/AIDS Program List*
Insulin isophane (NPH) intermediate 100 IU/ml, in 10 ml vial, injection vial [A10AC03inj]
Insulin isophane (NPH) intermediate 40 IU/ml, in 10 ml vial, injection vial [A10AC03inj]
Insulin soluble fast 100 IU/ml, in 10 ml vial, injection vial [A10AB01inj]
Insulin soluble fast 40 IU/ml, in 10 ml vial, injection vial [A10AB01inj]
Intrauterine device with copper 1 pce per piece, vaginal intrauterine device [G02BA02] *See: National Family Planning Program List*
Iodine 200 mg per capsule, oral ingestion capsule [H03CA20or]
Iodine 480 mg/ml, in 0.5 ml ampoule, oral ampoule [H03CA20or]
Iodine 540 mg/ml, in 0.57 ml bottle, oral solution [H03CA20or]
Iron dextran 50 mg/ml, in 2 ml ampoule, injection solution [B03AC06inj]
Iosfuran in 250 ml, gas [N01AB06]
Isoniazid (INH) 100 mg per tablet, oral ingestion tablet [J04AC01or] *See: National Tuberculosis Program List*
Isoniazid (INH) 300 mg per tablet, oral ingestion tablet [J04AC01or] *See: National Tuberculosis Program List*
Isoniazid (INH) 50 mg per tablet, oral ingestion tablet [J04AC01or] *See: National Tuberculosis Program List*
Isosorbide dinitrate 10 mg per tablet, sublingual-oral tablet [C01DA08or]
Isosorbide dinitrate 20 mg per tablet, sublingual-oral tablet [C01DA08or]
Isosorbide dinitrate 5 mg per tablet, sublingual-oral tablet [C01DA08or]

K

Ketamine 50 mg/ml, in 10 ml vial, injection solution [N01AX03inj]
Ketoconazole 2% in 15 g tube, topical cream [D01AC08]
Ketoconazole 2% in 60 ml, topical shampoo [D01AC08]
Ketoconazole 200 mg per tablet, oral ingestion tablet [J02AB02or]

L

Lactulose 3.33 g/5 ml, in 150 ml bottle, oral ingestion syrup [A06AD11or]
Lamivudine (3TC) 100 mg per tablet, oral ingestion tablet [J05AF05or] *See: National HIV/AIDS Program List*
Lamivudine (3TC) 150 mg per tablet, oral ingestion tablet [J05AF05or] *See: National HIV/AIDS Program List*
Lamivudine (3TC) 300 mg per tablet, oral ingestion tablet [J05AF05or] *See: National HIV/AIDS Program List*
Lamivudine (3TC) 50 mg/5 ml, oral ingestion suspension [J05AF05or] *See: National HIV/AIDS Program List*
Lamivudine 150 mg + nevirapine 200 mg + zidovudine 300 mg (AZT/3TC/NVP) per tablet, oral ingestion tablet [J05AR05or] *See: National HIV/AIDS Program List*
Lamivudine 150 mg + zidovudine 300 mg (AZT/3TC) per tablet, oral ingestion tablet [J05AR01or] *See: National HIV/AIDS Program List*
Lamivudine 150 mg + zidovudine 300 mg (AZT/3TC) per tablet, oral ingestion tablet [J05AR10or]
Lamivudine 150 mg + zidovudine 300 mg (AZT/3TC) per tablet, oral ingestion tablet [J05AR10or] *See: National HIV/AIDS Program List*
Lamivudine 40 mg + stavudine 10 mg (d4T/3TC)/5 ml, oral solution [J05AR09or]
Levothyroxine 0.05 mg per tablet, oral ingestion tablet [H03AA01]
Levothyroxine 0.1 mg per tablet, oral ingestion tablet [H03AA01or]
Levonorgestrel 0.03 mg per tablet, oral ingestion tablet [G03AC03or]
Lidocaine 1% in 2 ml, injection vial [N01BB02inj]
Lidocaine 2% in 15 g tube, topical gel [D04AB04]
Lidocaine 2% in 2 ml ampoule, injection solution [N01BB02inj]
Lidocaine 20 mg/ml, in 5 ml ampoule, injection solution [C01BB01inj]
Lidocaine 4% topical gel [N01BB02]
Lindane 1% topical shampoo [P03AB02]
Lopinavir 123.3 mg + ritonavir 33.3 mg (LPV/r) per capsule, oral ingestion capsule [J05AR10or] *See: National HIV/AIDS Program List*
Lopinavir 200 mg + ritonavir 50 mg (LPV/r) per capsule, oral ingestion capsule [J05AR10or]
Lopinavir 400 mg + ritonavir 100 mg (LPV/r) per 5 ml, oral ingestion liquid [J05AR10or] *See: National HIV/AIDS Program List*

M

Magnesium sulfate 500 mg/ml, in 10 ml ampoule, injection solution [N03AX31inj]
Magnesium sulfate 500 mg/ml, in 20 ml ampoule, injection solution [N03AX31inj]
Magnesium sulfate 500 mg/ml, in 2 ml ampoule, injection solution [N03AX31inj]
Mannitol 10% in 100 ml bottle, infusion solution [B05BC01inj]
Mannitol 20% in 100 ml bottle, infusion solution [B05BC01inj]
Maraviroc 150 mg per tablet, oral ingestion tablet [J05AX09or] *See: National HIV/AIDS Program List*
Maraviroc 300 mg per tablet, oral ingestion tablet [J05AX09or] *See: National HIV/AIDS Program List*
Measles diluent 10 doses per vial, injection vial [J07BD01inj]
Measles vaccine 10 doses per vial, injection vial [J07BD01inj]
Mebendazole 100 mg per tablet, oral chewable tablet [P02CA01or]
Methylergometrine maleate 0.2 mg/ml, in 1 ml, injection ampoule [G02AB01inj]
Methylrosaniline (gentian violet) 0.5% in 10 ml bottle, topical solution [D01AE02]
Methylrosaniline (gentian violet) 1% in 10 ml bottle, topical solution [D01AE02]
Methylrosaniline (gentian violet) 25 g per bottle, topical crystals [D01AE02]
Metoclopramide 10 mg per tablet, oral ingestion tablet [A03FA01or]
Metoclopramide 5 mg/ml, in 2 ml, injection solution [A03FA01inj]
Metoprolol 1 mg/ml, in 5 ml ampoule, injection solution [C07AB02inj]
Metoprolol 50 mg per tablet, oral ingestion tablet [C07AB02or]
Metronidazole 0.75% in 15 g tube, topical ointment [D06BX01]
Metronidazole 200 mg/5 ml, in 60 ml bottle, oral ingestion suspension [P01AB01or]
Metronidazole 200 mg per tablet, oral ingestion tablet [P01AB01or]
Metronidazole 250 mg per tablet, oral ingestion tablet [P01AB01or]
Metronidazole 400 mg per tablet, oral ingestion tablet [P01AB01or]
Metronidazole 500 mg per tablet, oral ingestion tablet [P01AB01or]
Metronidazole 5 mg/ml, in 100 ml bottle, infusion solution [J01XD01inj]
Midazolam 1 mg/ml, in 1 ml ampoule, injection solution [N05CD08inj]
Misoprostol 200 mcg per tablet, oral ingestion tablet [G02AD20or]
Misoprostol 25 mcg per tablet, vaginal tablet [G02AD06vg]
Morphine (sulfate, hydrochloride) 10 mg/ml, in 1 ml ampoule, injection solution [N02AA01inj]
Nalidixic acid 250 mg/5 ml, in 60 ml bottle, oral ingestion suspension [J01MB02or]
Nalidixic acid 250 mg per tablet, oral ingestion tablet [J01MB02or]
Naloxone 400 mcg/ml, in 1 ml, injection solution [V03AB15inj]
Naphazoline 0.05% in 10 ml bottle, nasal drop [R01AA08]
Nelfinavir (NFV) 200 mg/5 ml, oral ingestion suspension [J05AE04or] *See: National HIV/AIDS Program List*
Nelfinavir (NFV) 250 mg per tablet, oral ingestion tablet [J05AE04or] *See: National HIV/AIDS Program List*
Nelfinavir (NFV) 50 mg/g in 144 g pack, oral ingestion powder [J05AE04or] *See: National HIV/AIDS Program List*
Nelfinavir (NFV) 625 mg per tablet, oral ingestion tablet [J05AE04or] *See: National HIV/AIDS Program List*
Neomycin sulfate 0.5% in 15 g tube, topical cream [S01AA03]
Neostigmine bromide 15 mg per tablet, oral ingestion tablet [N07AA01or]
Neostigmine methylsulfate 0.5 mg/ml, in 10 ml, injection solution [N07AA01inj]
Nifedipine 10 mg per tablet, oral ingestion tablet [G02CA04or]
Nifedipine 20 mg per capsule, oral ingestion capsule [G02CA04or]
Nifedipine slow-release 10 mg per tablet, oral ingestion tablet [C08CA05or]
Nifedipine slow-release 20 mg per tablet, oral ingestion tablet [C08CA05or]
Nitrofurantoin 100 mg per tablet, oral ingestion tablet [J01XE01or]
Norethisterone 5 mg per tablet, oral ingestion tablet [G03DC02or]
Norgestrel 0.075 mg per tablet, oral ingestion tablet [G03AC10or] *See: National Family Planning Program List*
Nortriptiline 10 mg per tablet, oral ingestion tablet [N06AA10or]
Nystatin 100,000 IU/g, in 15 g tube, vaginal cream [G01AA01vg]
Nystatin 100,000 IU/g, in 25 g tube, topical cream [D01AA01]
Nystatin 100,000 IU/ml, in 15 ml, oral topical drop [A07AA02or]
Nystatin 100,000 IU per ovule, vaginal suppository [G01AA01vg]
Nystatin 100,000 IU per tablet, oral ingestion tablet [A07AA02or]
Nystatin 500,000 IU per tablet, vaginal tablet [A07AA01vg]
Nystatin 500,000 IU per tablet, oral ingestion tablet [A07AA02or]

Omeprazole 20 mg per capsule, oral ingestion capsule [A02BC01or]
Omeprazole 40 mg per capsule, oral ingestion capsule [A02BC01or]
Opium tincture 10% oral solution [N07BC59or] *See: National Drug Dependency Reduction Program*
Oral polio vaccine–bivalent (OPV-B) 20 doses per vial, oral vaccine [J07BF01or]
Oral polio vaccine–monovalent (OPV-M) 20 doses per vial, oral vaccine [J07BF01or]
Oral polio vaccine–triavalent (OPV-T) 20 doses per vial, oral vaccine [J07BF02or]
Oral rehydration salts (ORS) 20.5 g/L in 1 L sachet, oral powder [A07CA01or]
Oral rehydration salts (ORS) 27.9 g/L in 1 L sachet, oral powder [A07CA01or]
Oral rehydration salts (ORS ReSoMal) in 1 L sachet, oral ingestion powder [A07CA01or]

EML - Version of July 2014
Para-aminosalicylic acid (PAS) 4 g per sachet, oral ingestion granules [J04AA01or] *See: National Tuberculosis Program List*

Paracetamol (acetaminophen) 100 mg/ml in 15 ml bottle, oral ingestion drop [N02BE01or]
Paracetamol (acetaminophen) 100 mg per tablet, oral ingestion tablet [N02BE01or]
Paracetamol (acetaminophen) 120 mg/5 ml in 60 ml bottle, oral syrup [N02BE01or]
Paracetamol (acetaminophen) 125 mg per suppository, rectal suppository [N02BE01rec]
Paracetamol (acetaminophen) 325 mg per tablet, oral ingestion tablet [N02BE01or]
Paracetamol (acetaminophen) 500 mg per tablet, oral ingestion tablet [N02BE01or]
Paracetamol (acetaminophen) 125 mg per tablet, oral ingestion tablet [M01CC01or]
Paracetamol (acetaminophen) 250 mg per tablet, oral ingestion tablet [M01CC01or]
Penicillin benzyl (peni G crystal) 1 MU per vial, injection vial [J01CE01inj]
Penicillin benzyl (peni G crystal) 0.5 MU + penicillin procaine 1.5 MU per vial, injection vial [J01CE09inj]
Penicillin benzyl 1 MU + penicillin procaine 3 MU per vial, injection vial [J01CE09inj]
Penicillin benzyl 4 MU per vial, injection vial [J01CE09inj]
Penicillin V (phenoxymethylpenicillin) 500 mg per tablet, oral ingestion tablet [J01CE02or]
Peritoneal dialytics, isotonic solutions 1,000 ml per bag, parenteral solution [B05DA00]
Permethrin 1% in 60 ml bottle, topical lotion [P03AC04]
Pethidine 100 mg per tablet, oral ingestion tablet [N02AB02or]
Pethidine 50 mg/ml, injection solution [N02AB02inj]
Phenobarbital 100 mg/ml, in 2 ml, injection solution [N03AA02inj]
Phenobarbital 50 mg/ml, in 2 ml, injection solution [N03AA02inj]
Phenytoin 10 mg/ml, in 1 ml, injection solution [N05AA01inj]
Phenylbutazone 50 mg/ml, in 1 ml, injection solution [N02BA05inj]
Phenylbutazone 50 mg/ml, in 2 ml, injection solution [N02BA05inj]
Phenylpropanolamine 10 mg/ml, in 100 ml bottle, oral suspension [J01DA02or]
Phenylpropanolamine 10 mg/ml, in 20 ml bottle, oral suspension [J01DA02or]
Pilocarpine 2% in 15 ml bottle, ophthalmic drop [S01EB01]
Pilocarpine 4% in 15 ml bottle, ophthalmic drop [S01EB01]
Pneumococcal conjugated vaccine 23-valent single dose per vial, injection vial [J07AL02inj]
Pneumococcal conjugated vaccine 7-valent single dose per vial, injection vial [J07AL02inj]
Potassium chloride 11.2% in 20 ml ampoule, injection solution [B05XA01inj]
Potassium iodide 60 mg per tablet, oral ingestion tablet [V03AB21or]
Potassium permanganate 0.01% topical solution [D08AX06]
Povidone iodine 10% topical solution [D08AG02]
Prednisolone 0.5% in 5 ml bottle, ophthalmic drop [S01BA04]
Prednisolone 1% in 5 ml bottle, ophthalmic drop [S01BA04]
Primaquine 7.5 mg per tablet, oral ingestion tablet [P01BA03or] *See: National Malaria and Leishmania Control Program List*

Primaquine 15 mg per tablet, oral ingestion tablet [P01BA03or] *See: National Malaria and Leishmania Control Program List*
Propranolol 10 mg per tablet, oral ingestion tablet [C07AA05or]
Propranolol 20 mg per tablet, oral ingestion capsule or tablet [C07AA05or]
Propranolol 40 mg per tablet, oral ingestion tablet [C07AA05or]
Protamine sulfate 10 mg/ml, in 5 ml ampoule, injection solution [V03AB14inj]
Pyrazinamide (PZA) 150 mg per tablet, oral ingestion tablet [J04AK01or] *See: National Tuberculosis Program List*
Pyrazinamide (PZA) 400 mg per tablet, oral ingestion tablet [J04AK01or] *See: National Tuberculosis Program List*
Pyrazinamide (PZA) 500 mg per tablet, oral ingestion tablet [J04AK01or] *See: National Tuberculosis Program List*
Pyridoxine (vit B6) 25 mg per tablet, oral ingestion tablet [A11HA02or]
Pyridoxine (vit B6) 40 mg per tablet, oral ingestion tablet [A11HA02or]

*See: National Tuberculosis Program List*

Quinine dihydrochloride 300 mg/ml, in 2 ml ampoule, injection solution [P01BC01inj]
Quinine sulfate 300 mg per tablet, oral ingestion tablet [P01BC01or] *See: National Malaria and Leishmania Control Program List*

*See: National Tuberculosis Program List*

Rabies antitoxin 150 mg/ml, in 1 ml, injection vial [J06AA06inj]
Raltegravir 400 mg per tablet, oral ingestion tablet [J05AX08or] *See: National HIV/AIDS Program List*
Ranitidine 150 mg per tablet, oral ingestion tablet [A02BA02or]
Ranitidine 25 mg/ml, in 2 ml ampoule, injection solution [A02BA02inj]
Ranitidine 300 mg per tablet, oral ingestion tablet [A02BA02or]
Retinol (oily) (vit A) 100,000 IU/ml, oral solution [A11CA01or]
Retinol (vit A) 100,000 IU/ml, oral solution [A11CA01or]
Retinol (vit A) 200,000 IU/ml, oral solution [A11CA01or]
Retinol (vit A) 850 IU + colecalciferol (vit D3) 85 IU/g, in 30 g tube, topical ointment [D02AX00]
Rifampicin 150 mg per tablet or capsule, oral ingestion tablet or capsule [J04AB02or]
Rifampicin 300 mg per tablet or capsule, oral ingestion tablet or capsule [J04AB02or]
Rifampicin 150 mg + isoniazid 75 mg (RH) per tablet, oral ingestion tablet [J04AM02or] *See: National Tuberculosis Program List*
Rifampicin 150 mg + isoniazid 75 mg + ethambutol 275 mg (RHE) per tablet, oral ingestion tablet [J04AM07or] *See: National Tuberculosis Program List*
Rifampicin 300 mg + dapsone 50 mg + clofazimine 50 mg per tablet, oral ingestion tablet [J04BA01or] *See: National Leprosy Program List*
Rifampicin 60 mg + isoniazid 30 mg (RH) per tablet, oral ingestion tablet [J04AM02or] *See: National Tuberculosis Program List*
Rifampicin 60 mg + isoniazid 30 mg + pyrazinamide 150 mg (RHZ) per tablet, oral ingestion tablet [J04AM05or] *See: National Tuberculosis Program List*
Rifampicin 150 mg + isoniazid 75 mg + pyrazinamide 400 mg + ethambutol 275 mg (RHZE) per tablet or capsule, oral ingestion tablet or capsule [J04AM06or] *See: National Tuberculosis Program List*
Ringer’s lactate in 1,000 ml, infusion solution [B05BB01inj]
Ringer’s lactate in 500 ml, infusion solution [B05BB01inj]
Ritonavir (RTV) 100 mg per tablet, oral ingestion tablet [J05AE03or] *See: National HIV/AIDS Program List*
Ritonavir (RTV) 400 mg/5 ml, oral ingestion liquid [J05AE03or] *See: National HIV/AIDS Program List*
Rotavirus monovalent/pentavalent single or double dose in 2 vials, oral vaccine [J07BH01or]
Rubella vaccine, live attenuated in single dose, injection vial [J07BJ01inj]

Salbutamol 0.05 mg/ml, in 5 ml ampoule, injection solution [R03CC02inj]
Salbutamol 0.5 mg/ml, in 1 ml ampoule, injection solution or vial [R03CC02inj]
Salbutamol 0.1 mg per dose, in 200 dose bottle, inhalation solution [R03AC02has]
Salbutamol 2 mg/5 ml, in 60 ml bottle, oral syrup [R03CC02or]
Salbutamol 2 mg per tablet, oral ingestion tablet [R03CC02or]
Salbutamol 4 mg per tablet, oral ingestion tablet [R03CC02or]
Salbutamol 5 mg/ml, nebulizer solution [R03AC02hsl]
Salicylic acid 5% topical solution [D01AE12]
Saquinavir (SQV) 200 mg per capsule, oral ingestion capsule [J05AE01or] *See: National HIV/AIDS Program List*
Saquinavir 200 mg + ritonavir 500 mg (SQV/r) per tablet, oral ingestion tablet [J05AR08or]
Scorpion antivenom in 5 ml, injection vial [J06AA20inj]
Silver sulfadiazine 1% in 500 g container, topical cream [D06BA01]
Silver sulfadiazine 1% in 20g tube, topical cream [D06BA01]
Sodium bicarbonate 1.4% in 20 ml vial, injection vial [B05CB04inj]
Sodium bicarbonate 8.4% in 10 ml vial, injection vial [B05CB04inj]
Sodium chloride 0.65% in 10 ml, nasal drop [R01AX30]
Sodium chloride 0.9% in 1,000 ml bottle, injection solution [B05BB01inj]
Sodium chloride 0.9% in 500 ml bottle, injection solution [B05BB01inj]
Sodium hypochlorite (chlorine) 0.5% topical solution [D08AX07]
Sodium stibogluconate 100 mg/ml, injection solution [P01CB02inj] *See: National Malaria and Leishmania Control Program List*

- Spironolactone 25 mg per tablet, oral ingestion tablet [C03DA01or]
- Spironolactone 50mg per tablet, oral ingestion tablet [C03DA01or]
- Stavudine 30 mg + lamivudine 150 mg (d4T/3TC) per tablet, oral ingestion tablet [J05AR09or]
- Stavudine 40 mg + lamivudine 150 mg (d4T/3TC) per tablet, oral ingestion tablet [J05AR09or]
- Streptomycin (STM) 1 g per vial, injection vial [J04AB31inj] *See: National Tuberculosis Program List*
- Streptomycin 1 g per vial, injection vial [J01GA01inj]
- Sulfacetamide 10% in 15 ml bottle, ophthalmic drop [S01AB04]
- Sulfacetamide 20% in 15 ml bottle, ophthalmic drop [S01AB04]
- Sulfamethoxazole 100 mg + trimethoprim 20 mg (co-trimoxazole) per tablet, oral ingestion tablet [J01EE01or]
- Sulfamethoxazole 200 mg + trimethoprim 40 mg (co-trimoxazole) / 5 ml, in 50 ml bottle, oral ingestion suspension [J01EE01or]
- Sulfamethoxazole 400 mg + trimethoprim 80 mg per tablet (co-trimoxazole), oral ingestion tablet [J01EE01or]
- Sulfasalazine 500 mg per tablet, oral ingestion tablet [M01CX02or]
- Sulfur 2% + salicylic acid 1% topical ointment [D10AB02]
- Suxamethonium 50 mg/ml, in 2 ml ampoule, injection solution [M03AB01inj]

T

- Terbinafine 1% in 30 g tube, topical cream [D01AE15]
- Terbinafine 125 mg per tablet, oral ingestion tablet [D01BA02or]
- Terbinafine 250 mg per tablet, oral ingestion tablet [D01BA02or]
- Tetanus toxoid vaccine 20 dosed per vial, injection vial [J07AM01inj]
- Tetracaine 0.5% in 15 ml bottle, ophthalmic drop [S01HA03]
- Tetracycline 1% in 5 g, ophthalmic ointment [S01AA09]
- Thiopental sodium 1 g per vial, injection powder [N01FA03inj]
- Timolol 0.25% in 5 ml bottle, ophthalmic drop [S01ED01]
- Timolol 0.5% in 5 ml bottle, ophthalmic drop [S01ED01]
- Tramadol 50 mg per capsule, oral ingestion capsule [N02AX02or]
- Tramadol 50 mg/ml, in 2 ml, injection solution [N02AX02inj]
- Trihexyphenidyl 2 mg per tablet, oral ingestion tablet [N04AA01or]
- Tropicamide 0.5% in 15 ml bottle, ophthalmic drop [S01FA06]
- Tropicamide 1% in 3 ml bottle, ophthalmic drop [S01FA06]
- Tuberculin purified protein derivative 100 IU/ml, injection solvent [V04CF01]
- Tuberculin purified protein derivative 10 IU/ml, injection solvent [V04CF01]
- Tuberculosis vaccine (BCG) with diluent 20 doses per vial, injection vial [J07AN01inj]

V

- Valproic acid (sodium valproate) 200 mg per tablet, oral ingestion tablet [N03AG01or]
- Valproic acid (sodium valproate) 500 mg per tablet, oral ingestion tablet [N03AG01or]
- Vaseline [V99AB00]
- Verapamil 2.5 mg/ml, in 2 ml ampoule, injection solution [C08DA01inj]
- Verapamil 40 mg per tablet, oral ingestion tablet [C08DA01or]
- Verapamil 80 mg per tablet, oral ingestion tablet [C08DA01or]
- Vit A 400 mcg + vit C 30 mg + vit D 5 mcg + vit E 5 mg + vit B1 0.5 mg + riboflavin 0.5 mg + niacin (vit B3) 6 mg + pyridoxine (vit B6) 0.5 mg + cyanocobalamin (vit B12) 0.9 mcg + folic acid (vit B9) 150 mcg + iron 10 mg + zinc 4.1 mg + copper 0.56 mg + selenium 17 mcg + iodine (multiple micronutrient) per sachet [A11AA03or]
- Vit A 400 mcg + vit C 30 mg + vit D 5 mcg + vit E 5 mg + vit B1 0.5 mg + riboflavin 0.5 mg + niacin (vit B3) 6 mg + pyridoxine (vit B6) 0.5 mg + cyanocobalamin (vit B12) 0.9 mcg + folic acid (vit B9) 150 mcg + iron 10 mg + zinc 4.1 mg + copper 0.56 mg + selenium 17 mcg + iodine 90 mcg (multiple micronutrient) per tablet [A11AA03or]

W

- Water for injection, in 10 ml ampoule, injection solution [V07AB01inj]
- Water for Injection, in 5 ml ampoule, injection solution [V07AB01inj]

Z

- Zidovudine (AZT) 100 mg per capsule, oral ingestion capsule [J05AF01or] *See: National HIV/AIDS Program List*
- Zidovudine (AZT) 10 mg/ml, in 20 ml vial, injection solution [J05AF01inj] *See: National HIV/AIDS Program List*
- Zidovudine (AZT) 250 mg per capsule or tablet, oral ingestion capsule or tablet [J05AF01or] *See: National HIV/AIDS Program List*
- Zidovudine (AZT) 300 mg per tablet, oral ingestion tablet [J05AF01or] *See: National HIV/AIDS Program List*
- Zidovudine (AZT) 50 mg/5 ml, oral ingestion suspension [J05AF01or] *See: National HIV/AIDS Program List*
- Zinc oxide 10% in 20 g tube, topical ointment [D02AB01]
- Zinc oxide 20% in 20 g tube, topical cream [D02AB01]
- Zinc sulfate 10 mg per tablet, oral ingestion tablet, blister pack of 10 [A12CB01or]
- Zinc sulfate 20 mg per tablet, oral ingestion tablet, blister pack of 10 [A12CB01or]
Special Programs List

National Family Planning Program List

Items on the National Family Planning Program list can be imported and used by the private and public sector. In public sector health facilities, they should be used as per specifications in the BPHS or EPHS.

- Condom with and without nonoxinol 1 pce per piece, topical
- Ethinylestradiol 0.035 mg + norethisterone 1 mg per tablet, oral ingestion tablet
- Ethinylestradiol 0.03 mg + norgestrel 0.3 mg per tablet, oral ingestion tablet
- Ethinylestradiol 0.03mg+Levonorgestrel 0.15mg per tablet, oral ingestion tablet
- Intrauterine device with copper 1 pce per piece, vaginal intrauterine device
- Medroxyprogesterone acetate depot 150 mg/ml, in 1 ml vial, injection solution
- Levonorgestrel 0.03mg per tablet, oral ingestion tablet
- Levonorgestrel 0.075 mg per tablet, oral ingestion tablet

National Postpartum Hemorrhage Program List

Items on the National Postpartum Hemorrhage Program List can be imported and used only with explicit written approval and under supervision of the MoPH National Postpartum Hemorrhage Program, under Reproductive Health Directorate. The items included in this list are not for general or commercial use in the private sector.

- Misoprostol 200 mcg per tablet, oral ingestion tablet
- Misoprostol 25 mcg per tablet, vaginal tablet

National HIV/AIDS Program List and National Drug Demand Reduction List

Items on the National HIV/AIDS Program list can be imported and used by the private and public sector. They should only be dispensed on prescription. Items on the drug demand reduction program can be imported, manufactured and used as per Narcotics Medicines Laws, recommendations of Drug Demand Reduction Committee (DDRC), International Narcotics Control Board (INCB) and BPHS/EPHS specifications. These medicines are not for public use by private sector.

HIV/AIDS Medicines

Abacavir (ABC) 300 mg per tablet, oral ingestion tablet
Atazanavir 300 mg + ritonavir 100 mg (ATV/RTV) per tablet, oral ingestion tablet
Efavirenz (EFV) 100 mg per capsule, oral ingestion capsule
Efavirenz (EFV) 150 mg/5 ml, oral ingestion liquid
Efavirenz (EFV) 200 mg per capsule, oral ingestion capsule
Efavirenz (EFV) 50 mg per capsule, oral ingestion capsule
Efavirenz (EFV) 600 mg per tablet, oral ingestion tablet
Efavirenz 600 mg + emtricitabine 200 mg + tenofovir 300 mg (EFV/FTC/TDF) per tablet, oral ingestion tablet
Emtricitabine (FTC) 200 mg per capsule, oral ingestion capsule
Emtricitabine (FTC) 50 mg/5 ml, oral ingestion liquid
Emtricitabine 200 mg + tenofovir 300 mg (FTC/TDF) per tablet, oral ingestion tablet
Enfuvirtide 108 mg per vial, injection powder

EML - Version of July 2014
<table>
<thead>
<tr>
<th>Medicine</th>
<th>Formulation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Entecavir</td>
<td>0.5 mg per tablet, oral ingestion tablet</td>
</tr>
<tr>
<td>Efavirenz</td>
<td>25 mg per tablet, oral ingestion tablet</td>
</tr>
<tr>
<td>Indinavir (IDV)</td>
<td>200 mg per capsule, oral ingestion capsule</td>
</tr>
<tr>
<td>Indinavir (IDV)</td>
<td>333 mg per capsule, oral ingestion capsule</td>
</tr>
<tr>
<td>Indinavir (IDV)</td>
<td>400 mg per capsule, oral ingestion capsule</td>
</tr>
<tr>
<td>Indinavir 800 mg + ritonavir 100 mg (IDV/r)</td>
<td>per tablet, oral ingestion tablet</td>
</tr>
<tr>
<td>Lamivudine (3TC)</td>
<td>100 mg per tablet, oral ingestion tablet</td>
</tr>
<tr>
<td>Lamivudine (3TC)</td>
<td>150 mg per tablet, oral ingestion tablet</td>
</tr>
<tr>
<td>Lamivudine (3TC)</td>
<td>300 mg per tablet, oral ingestion tablet</td>
</tr>
<tr>
<td>Lamivudine (3TC)</td>
<td>50 mg/5 ml, oral ingestion suspension</td>
</tr>
<tr>
<td>Lamivudine 150 mg + nevirapine 200 mg + zidovudine 300 mg (AZT/3TC/NVP)</td>
<td>per tablet, oral ingestion tablet</td>
</tr>
<tr>
<td>Lamivudine 150 mg + zidovudine 300 mg (AZT/3TC)</td>
<td>per tablet, oral ingestion tablet</td>
</tr>
<tr>
<td>Lopinavir 133.3 mg + ritonavir 33.3 mg (LPV/r)</td>
<td>per capsule, oral ingestion capsule</td>
</tr>
<tr>
<td>Lopinavir 400 mg + ritonavir 100 mg (LPV/r)/5 ml,</td>
<td>oral ingestion liquid</td>
</tr>
<tr>
<td>Maraviroc</td>
<td>150 mg per tablet, oral ingestion tablet</td>
</tr>
<tr>
<td>Maraviroc</td>
<td>300 mg per tablet, oral ingestion tablet</td>
</tr>
<tr>
<td>Nelfinavir (NFV)</td>
<td>200 mg/5 ml, oral ingestion suspension</td>
</tr>
<tr>
<td>Nelfinavir (NFV)</td>
<td>250 mg per tablet, oral ingestion tablet</td>
</tr>
<tr>
<td>Nelfinavir (NFV)</td>
<td>50 mg per pack, oral powder</td>
</tr>
<tr>
<td>Nelfinavir (NFV)</td>
<td>625 mg per tablet, oral ingestion tablet</td>
</tr>
<tr>
<td>Nevirapine (NVP)</td>
<td>200 mg per tablet, oral ingestion tablet</td>
</tr>
<tr>
<td>Nevirapine (NVP)</td>
<td>50 mg/5 ml, oral ingestion liquid</td>
</tr>
<tr>
<td>Raltegravir</td>
<td>400 mg per tablet, oral ingestion tablet</td>
</tr>
<tr>
<td>Ritonavir (RTV)</td>
<td>100 mg per tablet, oral ingestion tablet</td>
</tr>
<tr>
<td>Ritonavir (RTV)</td>
<td>400 mg/5 ml, oral ingestion liquid</td>
</tr>
<tr>
<td>Saquinavir (SQV)</td>
<td>200 mg per capsule, oral ingestion capsule</td>
</tr>
<tr>
<td>Tenofovir (TDF)</td>
<td>300 mg per tablet, oral ingestion tablet</td>
</tr>
<tr>
<td>Tenofovir (TDF)</td>
<td>50 mg/5 ml, in 1 ml ampoule, oral ingestion tablet</td>
</tr>
<tr>
<td>Tenofovir (TDF)</td>
<td>10 mg/ml, in 60 ml, oral syrup</td>
</tr>
<tr>
<td>Tenofovir (TDF)</td>
<td>15 mg/5 ml, in 5 ml vial, injection solution</td>
</tr>
<tr>
<td>Tenofovir (TDF)</td>
<td>25 mg per capsule or tablet, oral ingestion capsule or tablet</td>
</tr>
<tr>
<td>Tenofovir (TDF)</td>
<td>300 mg per tablet, oral ingestion tablet</td>
</tr>
<tr>
<td>Tenofovir (TDF)</td>
<td>50 mg/5 ml, oral ingestion suspension</td>
</tr>
</tbody>
</table>

**National Drug Demand Reduction Medicines**

<table>
<thead>
<tr>
<th>Medicine</th>
<th>Formulation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Buprenorphine</td>
<td>2 mg per tablet, oral ingestion tablet</td>
</tr>
<tr>
<td>Buprenorphine</td>
<td>8 mg per tablet, oral ingestion tablet</td>
</tr>
<tr>
<td>Methadone</td>
<td>10 mg/ml, in 1 ml ampoule, injection solution</td>
</tr>
<tr>
<td>Methadone</td>
<td>10 mg/ml, oral solution</td>
</tr>
<tr>
<td>Methadone</td>
<td>10 mg per tablet, oral ingestion tablet</td>
</tr>
<tr>
<td>Methadone</td>
<td>5 mg/ml, oral solution</td>
</tr>
<tr>
<td>Methadone</td>
<td>5 mg per tablet, oral ingestion tablet</td>
</tr>
<tr>
<td>Opium tincture</td>
<td>10% oral solution</td>
</tr>
</tbody>
</table>

**National Malaria and Leishmania Control Program List**

Items on the National Malaria and Leishmania Control Program list can be imported and used by the private and public sector. In public sector health facilities, they should be used as per specifications in the BPHS or EPHS.

<table>
<thead>
<tr>
<th>Medicine</th>
<th>Formulation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Artemether</td>
<td>oily 20 mg/ml, injection solution</td>
</tr>
<tr>
<td>Artemether</td>
<td>oily 40 mg/ml, injection solution</td>
</tr>
<tr>
<td>Artemether</td>
<td>oily 80 mg/ml, injection solution</td>
</tr>
<tr>
<td>Artesunate</td>
<td>100 mg + pyrimethamine 25 mg + sulfadoxine 500 mg per tablet (co-blist), oral ingestion tablet</td>
</tr>
<tr>
<td>Artesunate</td>
<td>300 mg + pyrimethamine 50 mg + sulfadoxine 1,000 mg per tablet, oral ingestion tablet</td>
</tr>
<tr>
<td>Artesunate</td>
<td>50 mg + pyrimethamine 25 mg + sulfadoxine 500 mg per tablet, oral ingestion tablet</td>
</tr>
<tr>
<td>Artesunate</td>
<td>600 mg + pyrimethamine 75 mg + sulfadoxine 1,500 mg per tablet, oral ingestion tablet</td>
</tr>
<tr>
<td>Chloroquine</td>
<td>(base) 150 mg per tablet, oral ingestion tablet</td>
</tr>
<tr>
<td>Chloroquine</td>
<td>(base) 50 mg/5 ml, in 60 ml, oral syrup</td>
</tr>
<tr>
<td>Meglumine antimoniate</td>
<td>30% in 5 ml ampoule, injection solution</td>
</tr>
<tr>
<td>Primaquine</td>
<td>15 mg per tablet, oral ingestion tablet</td>
</tr>
<tr>
<td>Primaquine</td>
<td>7.5 mg per tablet, oral ingestion tablet</td>
</tr>
</tbody>
</table>
Quinine dihydrochloride 300 mg/ml, in 2 ml ampoule, injection solution
Quinine sulfate 300 mg per tablet, oral ingestion tablet
Sodium stibogluconate 100 mg/ml, injection solution

**National Tuberculosis Program List**

Items on the National Tuberculosis Program list can be imported and used by the private and public sector. In public sector health facilities, they should be used as per specifications in the BPHS or EPHS.

- Amikacin 500mg per milliliter, in 2ml vial, injection vial
- Capreomycin 1 g per vial, injection powder
- Cycloserine 250 mg per capsule, oral ingestion capsule
- Ethambutol (E) 275 mg + isoniazid 75 mg + pyrazinamide 400 mg + rifampicin 150 mg (RHZE) per tablet, oral tablet
- Ethambutol (EMB) 100 mg per tablet, oral ingestion tablet
- Ethambutol (EMB) 400 mg per tablet, oral ingestion tablet
- Ethambutol (EMB) 400 mg + isoniazid 150 mg per tablet, oral ingestion tablet
- Ethambutol 400 mg + isoniazid 75 mg (EH) per tablet, oral ingestion tablet
- Ethionamide 250 mg per tablet, oral ingestion tablet
- Isoniazid (INH) 100 mg per tablet, oral ingestion tablet
- Isoniazid (INH) 300 mg per tablet, oral ingestion tablet
- Isoniazid (INH) 50 mg per tablet, oral ingestion tablet
- Moxifloxacin 400 mg per tablet, oral ingestion tablet
- Para-aminosalicylic acid (PAS) 4 g per sachet, oral ingestion granules
- Pyrazinamide (PZA) 150 mg per tablet, oral ingestion tablet
- Pyrazinamide (PZA) 400 mg per tablet, oral ingestion tablet
- Pyrazinamide (PZA) 500 mg per tablet, oral ingestion tablet
- Rifampicin 150 mg + isoniazid 75 mg (RH) per tablet, oral ingestion tablet
- Rifampicin 150 mg + isoniazid 75 mg + ethambutol 275 mg (RHE) per tablet, oral ingestion tablet
- Rifampicin 60 mg + isoniazid 30 mg (RH) per tablet, oral ingestion tablet
- Rifampicin 60 mg + isoniazid 30 mg + pyrazinamide 150 mg (RHZE) per tablet, oral ingestion tablet
- Rifampicin 150 mg + isoniazid 75 mg + pyrazinamide 400 mg + ethambutol 275 mg (RHZE) per tablet, oral ingestion tablet or capsule
- Streptomycin (STM) 1 g per vial, injection vial

**National Leprosy Program List**

Items on the National Leprosy Program list can be imported and used by the private and public sector. In public sector health facilities, they should be used as per specifications in the BPHS or EPHS.

- Clofazimine (CLO) 100 mg per capsule, oral ingestion capsule
- Clofazimine (CLO) 50 mg per capsule, oral ingestion capsule
- Dapsone (DDS) 100 mg per tablet, oral ingestion tablet
- Dapsone (DDS) 25 mg per tablet, oral ingestion tablet
- Dapsone (DDS) 50 mg per tablet, oral ingestion tablet
- Rifampicin 300 mg + dapsone 50 mg + clofazimine 50 mg per tablet, oral ingestion tablet
- Rifampicin 600mg + Dapsone 100mg + Clofazimine 50mg per tablet, oral ingestion tablet
National EPI Program List
From the items on the EPI Program List, six vaccines (BCG, OPV, DPT-HepB-Hib, PCV1, Measles and TT) should be available in the public and private health facilities without charges and its sale in private and public health facilities are not allowed.

Diphtheria, pertussis, tetanus vaccine 20 doses per vial, injection vial
Diphtheria, pertussis, tetanus, HepB, Hib vaccine 20 doses per vial, injection vial
Diphtheria, pertussis, tetanus, Hepatitis B vaccine 10 doses per milliliter, injection vial
Measles vaccine 10 doses per vial, injection vial
Oral polio vaccine–bivalent (OPV-B) 20 doses per vial, oral vaccine
Oral polio vaccine–monovalent (OPV-M) 20 doses per vial, oral vaccine
Oral polio vaccine–trivalent (OPV-T) 20 doses per vial, oral vaccine
Pneumococcal conjugated vaccine 23-valent single dose per vial, injection vial
Pneumococcal conjugated vaccine 7-valent 1 dose per vial, injection vial
Rotavirus monovalent/pentavalent single or double dose in 2 vials, oral vaccine
Rubella vaccine, live attenuated in single dose, injection vial
Tetanus toxoid vaccine 20 doses per vial, injection vial
Tuberculosis vaccine (BCG) 20 doses per vial, injection vial

Reference Table for Vitamin and Mineral Supplements
Table 3 lists the limits, as defined by the Food and Nutrition Boards of the Institute of Medicine, U.S. National Academy of Sciences, for supplemental daily intake of vitamins and minerals.
Table 3. Reference Table for Vitamin and Mineral Supplements

<table>
<thead>
<tr>
<th>Acronym</th>
<th>ATC</th>
<th>Name</th>
<th>Form</th>
<th>Therapeutic Defined Daily Dose (adult)</th>
<th>Supplement Daily Intake</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Min.</td>
</tr>
<tr>
<td>Vit A</td>
<td>A11CA01</td>
<td>Retinol</td>
<td>Inj.</td>
<td>50 IU</td>
<td>0.4</td>
</tr>
<tr>
<td>Vit A</td>
<td>A11CA01</td>
<td>Retinol</td>
<td>Oral</td>
<td>50 IU</td>
<td>0.4</td>
</tr>
<tr>
<td>Vit B1a</td>
<td>A11DA01</td>
<td>Thiamine&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Inj.</td>
<td>50 mg</td>
<td>0.4</td>
</tr>
<tr>
<td>Vit B1a</td>
<td>A11DA01</td>
<td>Thiamine&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Oral</td>
<td>50 mg</td>
<td>0.4</td>
</tr>
<tr>
<td>Vit B12a</td>
<td>B03BA04</td>
<td>Cobamamide&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td>0.4</td>
</tr>
<tr>
<td>Vit B12a</td>
<td>B03BA01</td>
<td>Cyanocobalamin&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Nas.</td>
<td>0.07 mg</td>
<td>0.4</td>
</tr>
<tr>
<td>Vit B12a</td>
<td>B03BA01</td>
<td>Cyanocobalamin&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Oral</td>
<td>1 mg</td>
<td>0.4</td>
</tr>
<tr>
<td>Vit B12a</td>
<td>B03BA01</td>
<td>Cyanocobalamin&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Inj.</td>
<td>0.02 mg</td>
<td>0.4</td>
</tr>
<tr>
<td>Vit B12a</td>
<td>B03BA02</td>
<td>Cyanocobalamin tannin complex&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Inj.</td>
<td>0.02 mg</td>
<td>0.4</td>
</tr>
<tr>
<td>Vit B12a</td>
<td>B03BA03</td>
<td>Hydroxocobalamin&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Inj.</td>
<td>0.02 mg</td>
<td>0.4</td>
</tr>
<tr>
<td>Vit B12a</td>
<td>B03BA05</td>
<td>Mecobalamin&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Oral</td>
<td>1.5 mg</td>
<td>0.4</td>
</tr>
<tr>
<td>Vit B12a</td>
<td>B03BA05</td>
<td>Mecobalamin&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Inj.</td>
<td>0.2 mg</td>
<td>0.4</td>
</tr>
<tr>
<td>Vit B2a</td>
<td>A11HA04</td>
<td>Riboflavin&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td>0.3</td>
</tr>
<tr>
<td>Vit B3a</td>
<td>A11HA01</td>
<td>Nicotinamide&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Oral</td>
<td>150 mg</td>
<td>2</td>
</tr>
<tr>
<td>Vit B5a</td>
<td>A11HA31</td>
<td>Calcium pantothenate&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td>1.7</td>
</tr>
<tr>
<td>Vit B5a</td>
<td>A11HA30</td>
<td>Dexamethasone&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td>1.7</td>
</tr>
<tr>
<td>Vit B5a</td>
<td>A11HA32</td>
<td>Pantethine&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td>1.7</td>
</tr>
<tr>
<td>Vit B6a</td>
<td>A11HA06</td>
<td>Pyridoxal phosphate&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td>0.1</td>
</tr>
<tr>
<td>Vit B6a</td>
<td>A11HA02</td>
<td>Pyridoxine&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Oral</td>
<td>160 mg</td>
<td>0.1</td>
</tr>
<tr>
<td>Vit B6a</td>
<td>A11HA02</td>
<td>Pyridoxine&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Inj.</td>
<td>160 mg</td>
<td>0.1</td>
</tr>
<tr>
<td>Vit B7a</td>
<td>A11HA05</td>
<td>Biotin&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td>5</td>
</tr>
<tr>
<td>Vit B8a</td>
<td>A11HA07</td>
<td>Inositol&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vit B9a</td>
<td>B03BB01</td>
<td>Folic acid&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Oral</td>
<td>0.4 mg</td>
<td>0.065</td>
</tr>
<tr>
<td>Vit B9a</td>
<td>B03BB01</td>
<td>Folic acid&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Inj.</td>
<td>10 mg</td>
<td>0.065</td>
</tr>
<tr>
<td>Vit C&lt;sup&gt;a&lt;/sup&gt;</td>
<td>A11GA01</td>
<td>Ascorbic acid&lt;sup&gt;a&lt;/sup&gt; (therapy)</td>
<td>Inj.</td>
<td>200 mg</td>
<td>40</td>
</tr>
<tr>
<td>Vit C&lt;sup&gt;a&lt;/sup&gt;</td>
<td>A11GA01</td>
<td>Ascorbic acid&lt;sup&gt;a&lt;/sup&gt; (therapy)</td>
<td>Inj.</td>
<td>200 mg</td>
<td>40</td>
</tr>
<tr>
<td>Vit D</td>
<td>A11CC03</td>
<td>Alfacalcidol</td>
<td>Oral</td>
<td>0.001 mg</td>
<td></td>
</tr>
<tr>
<td>Vit D</td>
<td>A11CC03</td>
<td>Alfacalcidol</td>
<td>Inj.</td>
<td>0.001 mg</td>
<td></td>
</tr>
<tr>
<td>Vit D</td>
<td>A11CC06</td>
<td>Calcifediol</td>
<td></td>
<td></td>
<td>5</td>
</tr>
<tr>
<td>Vit D</td>
<td>A11CC04</td>
<td>Calciocitol</td>
<td>Oral</td>
<td>0.001 mg</td>
<td></td>
</tr>
<tr>
<td>Vit D</td>
<td>A11CC04</td>
<td>Calciocitol</td>
<td>Inj.</td>
<td>0.001 mg</td>
<td></td>
</tr>
<tr>
<td>Vit D</td>
<td>A11CC05</td>
<td>Colecalciferol</td>
<td></td>
<td></td>
<td>5</td>
</tr>
<tr>
<td>Vit D</td>
<td>A11CC05</td>
<td>Colecalciferol</td>
<td>Oral</td>
<td>1 mg</td>
<td>5</td>
</tr>
<tr>
<td>Vit D</td>
<td>A11CC05</td>
<td>Colecalciferol</td>
<td>Oral</td>
<td>1 mg</td>
<td>5</td>
</tr>
<tr>
<td>Vit D</td>
<td>A11CC07</td>
<td>Paricalcitol</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vit E</td>
<td>A11HA03</td>
<td>Tocopherol</td>
<td>Oral</td>
<td>200 mg</td>
<td>4</td>
</tr>
<tr>
<td>Vit E</td>
<td>A11HA03</td>
<td>Tocopherol</td>
<td>Inj.</td>
<td>200 mg</td>
<td>4</td>
</tr>
<tr>
<td>Vit K3</td>
<td>B02BA02</td>
<td>Menadione</td>
<td>Oral</td>
<td>10 mg</td>
<td>0.02</td>
</tr>
<tr>
<td>Vit K3</td>
<td>B02BA02</td>
<td>Menadione</td>
<td>Inj.</td>
<td>2 mg</td>
<td>0.02</td>
</tr>
<tr>
<td>Vit K3</td>
<td>B02BA01</td>
<td>Phytomenadione</td>
<td>Oral</td>
<td>20 mg</td>
<td>0.02</td>
</tr>
<tr>
<td>Vit K3</td>
<td>B02BA01</td>
<td>Phytomenadione</td>
<td>Inj.</td>
<td>20 mg</td>
<td>0.02</td>
</tr>
</tbody>
</table>

Calcium 210 1,000 mg
Chromium 0.2 45 mcg
Copper 0.34 13 mg
Fluoride 0.01 3 mg
Iodine 0.09 0.29 mg
Iron 0.27 9 mg
Magnesium 0.08 0.32 mg
Manganese 0.003 2.6 mg
Molybdenum 0.017 0.05 mg
Phosphor 450 700 mg
Selenium 0.02 0.07 mg
Zinc 2 12 mg

<sup>a</sup>Water soluble vitamins may exceed maximum strengths up to 20%.


General
The EML selection process is based on a well-developed procedure that ensures transparency of the inclusion process.

Applications for inclusion in the EML will be considered only if the application form has been fully completed for each proposed medicine. One application form must be filled out for each proposed medicine. An application for inclusion in the EML can be submitted only for medicines already on the LML list. If the applicant has urgent and compelling reasons for inclusion of a non-LML medicine in the EML, the request for inclusion in both the LML and EML can be submitted and will be processed at the same time. The following conditions must be met before an application for inclusion in the EML will be considered:

- The applicant’s contact details are complete.
- The medicine’s INN—including strength, route of administration, and presentation—has been provided.
- The indications have been clearly stated.
- The details of the proposed regimen for each indication are clearly stated.
- All relevant comparator medicines presently included in the EML have been listed for each indication.
- The applicant presents sufficient evidence to support the proposed amendment.
- A supporting letter from the relevant MoPH department or program is included.

The same format is used for proposing deletions from the list. Often the proposal for inclusion of one medicine will also indicate the medicine to be replaced with that medicine. The medicine to be replaced will be deleted. If an existing medicine should be deleted without replacement, the same format can be used, indicating the medicine to be deleted in section 4 without, however, proposing a new medicine for replacement in section 3, but mentioning “to be removed” in section 3.

Types of Applications
Applications may address major or minor amendments.

Minor amendments include, but are not limited to, the following:

- New strengths, presentations, or administration forms of medicines already included in the EML (e.g., proposing the inhalator form of a bronchodilator that is already included as tablet, or injection or proposing slow-release instead of common tablets).
- Combination therapies using medicines already included in the EML

For minor amendments, the required supporting evidence should be relevant to the nature of the amendment (e.g., alignment with new WHO recommendations on strengths or combination therapies requires only a copy of the new WHO recommendations) and should include cost implications.
Major amendments include, but are not limited to, the following:

- New indications for existing items on the list (e.g., using a medicine included for its antihypertension properties as a tocolytic)
- New therapeutic entities (e.g., a new antibiotic such as doxycycline to replace a previously included one such as tetracycline for the same indication)
- New therapeutic classes (e.g., antiretroviral medicines)

All major amendments must be supported by evidence reflecting safety, efficacy, and cost of the medicine compared to an already-listed medicine for the same indication. For inclusion of medicines already accepted in the LML list, reference to new MoPH guidelines, in line with WHO recommended practices may be sufficient. If the medicine is not on the LML list, please refer to the instructions in annex A of the LML.

Submittal and Screening Process

Applications are submitted to the GDPA of the MoPH. Upon receipt, the GDPA will acknowledge the receipt of the application in writing.

Applications are screened by the medicine technical selection committee (TSC) at the GDPA/MoPH to ensure that the following conditions have been met:

- The applicant’s contact details are included.
- The medicine can be identified by its INN (i.e., generic name).
- At least one indication has been included along with the proposed regimen and cost.
- Relevant comparator medicine(s) have been identified with their corresponding dosing regimen(s).
- The cited evidence to substantiate the application is valid.
- A supporting letter from the relevant MoPH department or program is included.

The TSC will compile a review of the prevailing cost of therapy and assign the application to a suitably qualified reviewer who will prepare a technical report. This technical report summarizes a review of the submitted data and supporting references in terms of the following:

- Relative safety—Are the side effects acceptable considering the benefits for the patient who has the indicated condition?
- Relative efficacy—How do treatment results compare with treatment results of existing medicines for the stated condition?
- Practice environment—How does the proposed medicine’s efficacy compare to current EML medicines?
- Pharmacoeconomic evaluation—How does the full treatment cost of the proposed medicine compare with the full treatment cost of existing medicines?
The report is then presented to the TSC, which may request further information from the applicant before recommending a decision to the NMSC.

The TSC will make one of the following recommendations to the NMSC for approval or rejection.

- If the NMSC decides that further review is required, the decision will be sent back to the TSC for further review.

- If the NMSC decides that the medicine is acceptable, the recommendation for approval will be submitted to the GDPA.

- If the NMSC decides that the medicine is not acceptable, the applicant will be informed of the rejection and of the reasons for rejection. A rejected medicine will not be reconsidered for inclusion within six months of the rejection. Resubmission requires significant additional information and supporting references that address the specific reason(s) for rejection of the original application.

**Detailed Description of the Application Form**

The application submission form contains five sections. Instructions for filling out the sections are provided here.

**Section 1. Proposed Medicine Identification**

- **Proposed Medicine:** Provide the proposed medicine’s INN, which identifies a pharmaceutical substance or active pharmaceutical ingredient by a unique name that is globally recognized and is public property. An INN is also known as a generic name. It also includes the presentation form and the strength of the proposed medicine (e.g., acetylsalicylic acid, tablet, 325 mg).

- **EML:** Indicate whether the proposed medicine should be included in the BPHS indicating the specific level(s), in the EPHS also indicating the specific level(s), or in both. If the medicine is intended for use by a special program or specialist physician, indicate the program or specialist in the special case.

- **Submission Date:** Give the Shamsi calendar date on which the submission is filled out.

**Section 2. Applicant’s Details**

The NMSC will acknowledge all submissions and communicate decisions with supporting arguments if appropriate. This section, therefore, forms a vital link between the applicant and the decision-making process.

- **Title:** give the full name of applicant with title

- **Name:** Give the full name of the applicant. Do not abbreviate (e.g., Mohammad, not Mhd.; Sayed, not S.).

- **Title/Department:** Provide the name of the department or entity for whom the applicant works.

- **Father’s Name:** Give the full name of the applicant’s father. Do not abbreviate (e.g., Mohammad, but Mhd.; Sayed, not S.).

- **Phone No.:** Give the phone number(s) at which the applicant can be contacted.
• **Postal Address:** Provide the full address where correspondence regarding the application should be sent. Include house number, street name, village or city, nahia, district, and province.

• **E-mail Address:** Give the e-mail address to which correspondence regarding the application can be sent.

• **Facility ID:** If applicable, provide the official MoPH facility code of the facility where the applicant works. If the applicant is a private practitioner, working in a nonregistered facility, put “NA” for this entry.

**Section 3. Proposed Indications**

For each medicine submitted for inclusion, at least one indication with proposed regimen needs to be filled out. Up to three indications can be filled out for one medicine submitted for inclusion.

• **Indication:** The applicant may list up to three indications (conditions) for using the suggested medicine. The following are points to consider:
  
  o If the applicant suggests a new therapeutic class (i.e., a new or emerging disease or condition), a brief evidence based on Afghan epidemiological data, as well as inclusion status in the BPHS, the EPHS, or an MoPH special program, must be included as an annex.
  
  o The indication should allow for the identification of the appropriate comparator(s) in the current EML.
  
  o Many medicines have multiple indications. Not all indications are equally cost effective, however.

• **Proposed Regimen**
  
  o **Dose:** The amount of the medicine to be given with each intake or administration
  
  o **Route:** For example, oral, parenteral, or topical
  
  o **Interval:** Expressed as one administration every so many hours
  
  o **Duration:** Number of days for a full treatment; for chronic conditions, write “30”

  These data will be used for cost comparison and are vital for the pharmacoeconomic evaluation of the application.

• **Cost Assessment:** Costs are expressed in either US dollars or Afghans. Only one currency should be used. Using US dollars may facilitate comparisons with medicines available on the international market. The cost assessment of the proposed medicine is filled out by the applicant and will be double checked by the TSC.
  
  o **Cost/Unit:** List the cost for one unit of the medicine. Clearly indicate the unit for which the cost is given.
  
  o **Cost/Course:** List the cost for a complete treatment, or for one month’s treatment for medicines used in chronic conditions.

  These data are necessary to determine affordability. The EML includes all medicines that are recommended for use in the public sector and eligible for subsidy to decrease costs for the patient and increase access to the medicines for the poor. For this reason, pharmacoeconomic data are considered mandatory for the decision to include a medicine in the EML.

• **Level of Evidence:** Cite, for each indication, the reference of the evidence that supports the use of the proposed medicine for that indication. Often this evidence will be the relevant
WHO document or a document from another internationally accepted reference.

Section 4. Medicines on the Current EML with the Same Indication

As a principle, the addition of an EML item should replace an existing item. This principle is of particular importance when safety and economic implications are taken into account. For each indication, the applicant will give at least one comparator medicine. For new therapeutic classes, a comparator medicine is not required. Details of the comparator medicine include the following:

- **Medicine INN** (generic name). List the presentation form and strength.
- **Indication**. Cite (one of) the indication(s) listed in section 3.
- **Current Regimen**. List the regimen as was done for the proposed medicine.
- **Cost Assessment**. The cost assessment of the comparator medicines is done by the TSC.
- **Can Be Replaced by the Proposed Medicine**. The TSC’s conclusion of the comparison between current medicine and the proposed medicine (Yes/No).

Section 5. For Use by Pharmacy Department Only

This section is intended to ensure that the submissions follow the proper process. Dates of steps and decisions will be noted as appropriate. The section will allow the interested parties to quickly review the history of an application.

- **Application Number**: Upon receipt, the serial number of the application is noted. It consists of the number of the form, the four digits of the year of submission, and the serial number of submission in that year.

- **Correspondence**
  - **Date Received**: The date the application was received.
  - **Date Acknowledged**: The date a message was sent to the applicant confirming receipt.
  - **Application for More Evidence**: If applicable, the date a request for more evidence was sent to the applicant. Only one request for more evidence will be sent per application for inclusion. Failure to submit convincing evidence will lead to rejection of the application.
  - **Supporting Letter**: The name of the MoPH department or program that supports the application for inclusion in the EML.
  - **Initial Evidence**: The number or name of the reference given as initial evidence.
  - **Additional Evidence**: The number or name of the reference given as additional evidence.
  - **Level of Evidence**
    - **Number of articles submitted initially**
    - **Number of articles submitted as additional evidence**

- **Advice of TSC**: Whether the application is accepted or rejected.

- **Reason for Application**: Summarizes the reason(s) for the application. More than one
option may be circled.

- **New Medicine:** Application for a new medicine that is not yet on the EML
- **New Strength or Presentation Form:** Application for a new strength or presentation form of a medicine already included in the EML
- **New or Changed Condition:** Application to extend the use of an existing medicine to a condition for which it was previously not used or the condition it was previously accepted for has been changed (e.g., split into two or more new conditions)
- **Change in Level of Care:** Application instigated by a change in STG or official MoPH protocols
- **New Therapeutic Class:** Application for new medicines that address newly emergent conditions (e.g., HIV/AIDS medicines)

- **Rejected by TSC:** The date the TSC rejected the application
- **Forward to NMSC:** The date the TSC forwarded the application for final acceptance
- **Accepted by NMSC:** The date the NMSC accepted the medicine for inclusion
- **Rejected by NMSC:** The date the NMSC rejected the medicine for inclusion
- **Signature and Stamp of API:** API director’s signature and stamp
- **Signatures and Stamp of GDPA:** GDPA director’s signature and stamp

The applicant will be informed in writing of the final decision. Figure A1 summarizes the application process.
Figure A1. Flow of application for inclusion in the EML

- Applicant submits application to GDPA
  - Request completion or additional evidence from applicant
    - Relevant data in sections 1, 2, and 3 are complete?
      - Yes
        - GDPA refers to API
          - Is mentioned Evidence Attached?
            - Yes
              - TSC reviews evidence
                - Additional information needed?
                  - No
                    - TSC forwards recommendation to NMSC
                      - NMSC requests further review?
                        - Yes
                          - NMSC accepts medicine for inclusion
                            - Inform applicant of NMSC decision
                            - Include product in EML
                        - No
                          - Inform applicant of NMSC decision
          - No
            - Applicant submits application to GDPA
              - Relevant data in sections 1, 2, and 3 are complete?
                - Yes
                  - GDPA refers to API
                    - Is mentioned Evidence Attached?
                      - Yes
                        - TSC reviews evidence
                          - Additional information needed?
                            - No
                              - TSC forwards recommendation to NMSC
                                - NMSC accepts medicine for inclusion
                                  - Inform applicant of NMSC decision
                                  - Include product in EML
                            - Yes
                              - TSC forwards recommendation to NMSC
                                - NMSC requests further review?
                                  - Yes
                                    - NMSC accepts medicine for inclusion
                                      - Inform applicant of NMSC decision
                                      - Include product in EML
                                  - No
                                    - Inform applicant of NMSC decision
                            - No
                              - TSC forwards recommendation to NMSC
                                - NMSC requests further review?
                                  - Yes
                                    - NMSC accepts medicine for inclusion
                                      - Inform applicant of NMSC decision
                                      - Include product in EML
                                  - No
                                    - Inform applicant of NMSC decision
                          - No
                            - TSC forwards recommendation to NMSC
                              - NMSC accepts medicine for inclusion
                                - Inform applicant of NMSC decision
                                - Include product in EML
                            - No
                              - TSC forwards recommendation to NMSC
                                - NMSC requests further review?
                                  - Yes
                                    - NMSC accepts medicine for inclusion
                                      - Inform applicant of NMSC decision
                                      - Include product in EML
                                  - No
                                    - Inform applicant of NMSC decision
                            - No
                              - TSC forwards recommendation to NMSC
                                - NMSC requests further review?
                                  - Yes
                                    - NMSC accepts medicine for inclusion
                                      - Inform applicant of NMSC decision
                                      - Include product in EML
                                  - No
                                    - Inform applicant of NMSC decision
                            - No
                              - TSC forwards recommendation to NMSC
                                - NMSC requests further review?
                                  - Yes
                                    - NMSC accepts medicine for inclusion
                                      - Inform applicant of NMSC decision
                                      - Include product in EML
                                  - No
                                    - Inform applicant of NMSC decision
                            - No
                              - TSC forwards recommendation to NMSC
                                - NMSC requests further review?
                                  - Yes
                                    - NMSC accepts medicine for inclusion
                                      - Inform applicant of NMSC decision
                                      - Include product in EML
                                  - No
                                    - Inform applicant of NMSC decision
                            - No
                              - TSC forwards recommendation to NMSC
                                - NMSC requests further review?
                                  - Yes
                                    - NMSC accepts medicine for inclusion
                                      - Inform applicant of NMSC decision
                                      - Include product in EML
                                  - No
                                    - Inform applicant of NMSC decision
                            - No
                              - TSC forwards recommendation to NMSC
                                - NMSC requests further review?
                                  - Yes
                                    - NMSC accepts medicine for inclusion
                                      - Inform applicant of NMSC decision
                                      - Include product in EML
                                  - No
                                    - Inform applicant of NMSC decision
                            - No
                              - TSC forwards recommendation to NMSC
                                - NMSC requests further review?
                                  - Yes
                                    - NMSC accepts medicine for inclusion
                                      - Inform applicant of NMSC decision
                                      - Include product in EML
                                  - No
                                    - Inform applicant of NMSC decision
                            - No
                              - TSC forwards recommendation to NMSC
                                - NMSC requests further review?
                                  - Yes
                                    - NMSC accepts medicine for inclusion
                                      - Inform applicant of NMSC decision
                                      - Include product in EML
                                  - No
                                    - Inform applicant of
Notes on the Application Process

Evidence

Evidence is a vital component of the submission and review process. Evidence does not constitute a medicine decision and merely informs the strength of the argument. It forms the basis upon which the decision is made and allows for transparent scrutiny of the decision as well as facilitating the review. Evidence is required in support of the following:

- Relative efficacy
- Relative safety
- Relative cost
- Pharmacoeconomic benefits

Evidence needs to be relevant to the Afghan context. Multinational or foreign studies must be supported by a motivation of the relevance of both the outcome measures as well as socioeconomic facets to the Afghan context. The inclusion of at least one relevant reference is mandatory.

For application of an existing medicine to a new indication or for the introduction of a new medicine or new class of medicines, a copy of the full journal article should be included to expedite the review process.

Communication of the Decision

After processing, the decision regarding an application will be communicated in writing to the applicant. In case of rejection of the application, the exact reasons for rejection will be provided.

Reconsidering a Rejected Application

As a rule, a rejected application will not be reconsidered within six months after the rejection. To qualify for reconsideration, compelling additional evidence as described above should accompany the resubmission.
**Application Form for Including or Excluding a Medicine in the EML**

<table>
<thead>
<tr>
<th>Section 1. Proposed Medicine Identification</th>
<th>Section 2. Applicant’s Details:</th>
</tr>
</thead>
<tbody>
<tr>
<td>بخش اول: معرفی دوای پیشنهادی</td>
<td>بخش دوم: تفصیلات درخواست کننده:</td>
</tr>
<tr>
<td>- این: (INN)</td>
<td>- نام:</td>
</tr>
<tr>
<td>- شکل دوایی Form:</td>
<td>- ولد:</td>
</tr>
<tr>
<td>- قدرت Strength:</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EML</th>
<th>افزودن/کاستن در</th>
</tr>
</thead>
<tbody>
<tr>
<td>BPHS</td>
<td>EPHS</td>
</tr>
<tr>
<td>HP</td>
<td>DH</td>
</tr>
<tr>
<td>BHC</td>
<td>PH</td>
</tr>
<tr>
<td>CHC</td>
<td>RH</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Title/Dept:</th>
<th>Phone No.:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Postal Address:</th>
<th>E-mail Address:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Health Facility ID:</th>
<th>کد شماره مرکز صحی</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>تاریخ ارائه درخواست:</td>
</tr>
</tbody>
</table>

| Submission Date: | |
|------------------| |

<table>
<thead>
<tr>
<th>بخش سوم: مشخصات دوای پیشنهاد شده</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Indication</th>
<th>ارژنی تداوی پیشنهادی</th>
<th>Proposed Regimen</th>
<th>Cost Assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td>بخش سوم: بخش</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Level of Evidence</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>سطح شواهد (E)</td>
<td>Ia. Meta-analysis</td>
<td>Ib. Randomized controlled trial</td>
<td></td>
</tr>
<tr>
<td>II. Controlled study with no randomization</td>
<td>III. Comparative, correlation, or case control study</td>
<td>IV. Reliable textbooks</td>
<td>V. Any other valid references</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cost</th>
<th>Cost</th>
<th>Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>قیمت/单一 Cost/Unit</td>
<td>قیمت کورس مکمل تداوی Cost/Course</td>
<td></td>
</tr>
</tbody>
</table>
### Section 4. Medicine on current EML or LML with the same indication

<table>
<thead>
<tr>
<th>Medicine</th>
<th>Dose</th>
<th>Indication</th>
<th>Current Regimen</th>
<th>Cost Assessment</th>
<th>Can be replaced by proposed medicine</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Dose</td>
<td>Route</td>
<td>Interval</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Section 5. For Use by Pharmacy Department Only

<table>
<thead>
<tr>
<th>Application Number:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Correspondence</td>
<td>Date Received</td>
</tr>
<tr>
<td>Date of Correspondence</td>
<td>Incident Date</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Supporting letter from:</th>
<th>Evidence</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial evidence</td>
<td>Additional evidence</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Evidence</th>
<th>Number of articles submitted initial</th>
<th>Number of articles submitted as additional evidence:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Advice of TSC:</th>
<th>Accept / Reject</th>
<th>Reason for application:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>New medicine</td>
<td>New strength or presentation form</td>
<td>New or changed condition</td>
<td></td>
</tr>
<tr>
<td>Change in level of care</td>
<td>New therapeutic class</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Rejected by TSC:</th>
<th>Forward to NMSC:</th>
<th>Accepted by NMSC:</th>
<th>Rejected by NMSC:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accept</td>
<td>/</td>
<td>/</td>
<td>/</td>
</tr>
<tr>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>API Director Signature:</th>
<th>GDPA Director Signature:</th>
</tr>
</thead>
<tbody>
<tr>
<td>API Stamp:</td>
<td></td>
</tr>
</tbody>
</table>

**Page 67 of 69**
References


Islamic Republic of Afghanistan. 2007. Licensed Drugs List of Afghanistan. Kabul: Drugs and Therapeutics Committee, Essential Drugs Department, Ministry of Health, and MoPH.


ABOUT SPS:
The Strengthening Pharmaceutical Systems (SPS) Program strives to build capacity within developing countries to effectively manage all aspects of pharmaceutical systems and services. SPS focuses on improving governance in the pharmaceutical sector, strengthening pharmaceutical management systems and financing mechanisms, containing antimicrobial resistance, and enhancing access to the most efficacious, safe and cost-effective medicines and appropriate use of medicines.